ketanserin has been researched along with Hypertension in 314 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The available data on the use of ketanserin in diabetes mellitus have been reviewed." | 10.16 | Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review. ( Janssens, M; Robertson, MP; Symoens, J, 1991) |
| "Determine the definitive position of ketanserin and dihydralazine for treatment of severe hypertension in pregnancy." | 9.20 | Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. ( Bijvank, SW; Duvekot, JJ; Edens, MA; Hanff, LM; Roofthooft, DW; Steegers, EA; Visser, W; Vulto, AG, 2015) |
| "To establish the optimal dosage of ketanserin in the treatment of severe hypertension in pregnancy." | 9.10 | The optimal dosage of ketanserin for patients with severe hypertension in pregnancy. ( de Jeu, RM; Odendaal, HJ; Steyn, DW; van Geijn, HP; van Schie, DL, 2002) |
| "The aim of the study was to compare antihypertensive efficacy and safety of ketanserin with those of enalapril in the treatment of hypertension." | 9.08 | [Cross-over study on the effects of ketanserin vs enalapril in the treatment of hypertension]. ( Guerini Rocco, C; Modica, G; Monte, I, 1995) |
| "The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients." | 9.08 | Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic-hyperinsulinemic clamp technique. ( Derosa, G; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1995) |
| "We found an association between the addition of ketanserin to aspirin and a decrease in the number of cases of pre-eclampsia and severe hypertension, as well as improved pregnancy outcome among patients with mild to moderate midtrimester hypertension." | 9.08 | Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. ( Odendaal, HJ; Steyn, DW, 1997) |
| " The need for delivery for fetal distress did not differ (3 after dihydralazine, 1 after ketanserin, P = 0." | 9.08 | Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. ( Odendaal, HJ; Steyn, DW, 1997) |
| "To compare the haemodynamic efficacy of ketanserin (a selective serotonin2-receptor blocker) with dihydralazine in the management of severe early-onset hypertension in pregnancy." | 9.08 | The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy. ( Bolte, AC; Dekker, GA; Strack van Schijndel, RJ; van Eyck, J; van Geijn, HP, 1998) |
| "Ketanserin, a serotonin-2-receptor antagonist, was administered to 16 patients with mild to moderate essential hypertension in randomized single-blind placebo controlled study." | 9.07 | [Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension]. ( Berent, H; Brym, E; Czerniewska, E; Januszewicz, W; Knypl, K; Kuçzyńska, K; Wacławek-Maczkowska, J; Wasowska, T; Wocial, B, 1993) |
| "The response of arterial BP and intracranial pressure to an intravenous injection of the serotonin antagonist, ketanserin, was recorded in ten patients with hypertension following intracerebral haemorrhage." | 9.07 | Effect of intravenous ketanserin on arterial and intracranial pressures in patients with systemic hypertension following intracerebral haemorrhage. ( Kay, R; Nicholls, MG; Poon, WS, 1993) |
| "In 51 patients with stage II essential hypertension (mild and moderate arterial hypertension), a cross-over study was carried out to estimate the efficacy of the use of ketanserin (KS), an antagonist of serotonin receptors, as compared to the efficacy of placebo, the beta-adrenoblocker propranolol (PP), the diuretic triampur and the beta 1-adrenoblocker prazosin." | 9.07 | [A cross-over study of ketanserin compared to placebo, beta-adrenergic blockader, diuretic and alpha 1-adrenergic blockader. Cooperative research in the USSR (the Cooperative Program to Study New Preparations in the Prevention of Arterial Hypertension). W ( Filatova, NP; Metelitsa, VI, 1991) |
| "The efficacy of ketanserin treatment (40 mg daily for 90 days) was evaluated in 88 patients with arterial hypertension combined with Leriche-Fontaine stage II obliterating arterial disease of the lower limbs." | 9.07 | [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin]. ( Mollo, P, 1991) |
| "The effect of ketanserin at 5 mg, 10 mg and 20 mg twice daily for 3 months was studied in Chinese patients with hypertension." | 9.07 | Ketanserin in the treatment of hypertension: a multicentre dose-finding study in China. ( Huang, DX; Liu, GS; Peng, SY; Tang, XL; Tong, YZ; Wang, SR; Xing, JL; Yang, XS, 1991) |
| "Forty patients with mild-to-moderate arterial hypertension were randomized for double-blind treatment with ketanserin (20 mg b." | 9.06 | [Short and medium term evaluation of captopril-ketanserin combination in mild to moderate arterial hypertension]. ( Barbara, C; Bruzzone, F; Canale, C; Masperone, MA; Provinciali, L; Romeo, M; Terrachini, V; Zanna, C, 1990) |
| "The effects of ketanserin, 40 mg/day (KE40) and 80 mg/day (KE80) on mean arterial pressure, lipids, lipoproteins, and circulating atrial natriuretic factor (ANF) were investigated in a 24-week controlled study in 29 patients suffering from mild to moderate hypertension." | 9.06 | Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension. ( Bielmann, P; Davignon, J; Gutkowska, J; Leduc, G, 1990) |
| "In order to assess the medium-term efficacy of ketanserin in comparison with that of the beta-blocker, propranolol, a randomized double-blind crossover trial was conducted involving 13 patients suffering from mild or moderate essential hypertension." | 9.06 | Ketanserin versus propranolol in the treatment of mild and moderate essential hypertension: corroboration with ambulatory blood pressure monitoring. ( Alaimo, G; Giordano, U; Novo, S; Raineri, A; Strano, A, 1987) |
| "We have studied the acute effects of the serotonergic type-2 (5-HT2) antagonists ketanserin and ritanserin given as single oral doses to patients with essential hypertension." | 9.06 | Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. ( Ball, SG; Hosie, J; Robertson, JI; Stott, DJ, 1987) |
| "Twenty patients requiring management of postoperative arterial hypertension following coronary artery bypass grafting (CABG) were randomly treated with either ketanserin (n = 10) or sodium nitroprusside (SNP) (n = 10)." | 9.06 | [Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation]. ( Lauwers, P; Möllhoff, T; Mulier, JP; Müller, E; Van Aken, H, 1989) |
| "Sixty patients, with mild to moderate essential hypertension, were considered for a double-blind trial comparing the effects of ketanserin and atenolol." | 9.06 | A double-blind comparative study of ketanserin with atenolol in essential hypertension. ( Andreoni, A; Antonicelli, R; Gambini, C; Paciaroni, E; Saccomanno, G, 1989) |
| "The safety and efficacy of ketanserin, a competitive serotonin blocking agent, and propranolol were compared in 33 patients with mild to moderate hypertension (sitting diastolic blood pressure [DBP] 95-115 mm Hg) using a placebo run-in, randomized, double-blind parallel study design." | 9.06 | Serotonergic blockade compared with beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin with propranolol. ( Charlap, S; Frishman, WH; Greenberg, S; Huberfeld, SI; Laifer, L; Lapsker, J; Okin, S; Soberman, J; Strom, JA, 1988) |
| " A trial was carried out on medium-term treatment with ketanserin or propranolol in subjects suffering from mild to moderate hypertension." | 9.06 | Effects of ketanserin on ambulatory blood pressure monitoring in patients with essential hypertension. ( Abrignani, MG; Alaimo, G; Cutietta, A; Novo, S; Raineri, A; Strano, A, 1986) |
| "The antihypertensive effects of ketanserin (40 mg twice daily) and pindolol (5 mg twice daily) as monotherapy were compared in a crossover, double-blind trial in 17 patients with essential hypertension." | 9.06 | Comparison of ketanserin and pindolol in hypertension. ( Gordin, A; Saraste, K; Sundberg, S; Turanlahti, M, 1986) |
| "The long-term safety and efficacy of ketanserin in the treatment of essential hypertension was assessed in monotherapy or in combination with the beta-blocker, metoprolol." | 9.06 | Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol. ( Mauersberger, H, 1986) |
| "Ketanserin (K), a selective and specific S2-receptor antagonist, has been compared with metoprolol (M), a cardioselective beta-blocker, in a double-blind study in order to assess its efficacy and safety in the treatment of essential hypertension." | 9.06 | Clinical experience with ketanserin in the treatment of hypertension. ( Assogna, G; Costantini, C; del Rosso, G; Libretti, A; Mara, G; Palermo, A; Pizza, N, 1986) |
| "5 years) with mild hypertension were considered for a double-blind trial comparing the effects of ketanserin and propranolol." | 9.06 | Ketanserin in the treatment of mild hypertension in elderly patients: preliminary results of a controlled double-blind trial. ( Dona, G; Ribeiro, A; Tammaro, AE, 1986) |
| "To clarify the antihypertensive effect, safety and clinical usefulness of ketanserin, a comparative double-blind study was carried out in 277 patients with essential hypertension using propranolol as a control drug." | 9.06 | Comparative double-blind study of ketanserin versus propranolol in the treatment of essential hypertension. ( Iimura, O; Ikeda, M; Ishii, M; Ito, K; Kaneko, Y; Masuyama, Y; Mizuno, Y; Omae, T; Takeda, T; Yoshinaga, K, 1988) |
| " The effect of ketanserin tartrate (20 to 60 mg daily), a new antihypertensive drug, on blood lipids was evaluated in a 12-week non-comparative clinical trial in 34 patients with mild or moderate hypertension." | 9.06 | Effects of ketanserin tartrate on serum lipids in patients with essential hypertension. ( Hirata, F; Homma, Y; Ishikawa, T; Mizuno, M; Nakamura, H; Nakaya, N; Saito, E; Tada, N; Takeuchi, I; Yasugi, T, 1988) |
| " In nine patients with essential hypertension, following single and multiple doses of ketanserin, assessments were made of blood pressure and heart rate, QT interval, and pressor responses to phenylephrine and angiotensin II." | 9.06 | Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "Thirteen men, age 60 +/- 2 years (mean +/- SEM) with mild hypertension, 151 +/- 4/95 +/- 3 mm Hg, completed a randomized, double-blind, placebo-controlled crossover trial of ketanserin therapy." | 9.06 | Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. ( Campbell, R; Conlon, ME; Egan, B; Julius, S; Schork, N; Zwiefler, A, 1988) |
| "Monotherapy with Ketanserin, a serotonin receptor antagonist, reduces blood pressure in a sizeable number of patients with essential hypertension." | 9.06 | Ketanserin in the treatment of essential hypertension. A double-blind study against metoprolol and a further long-term open treatment. ( Bernardiner, E; Lemus, J; Milei, J, 1986) |
| "Ketanserin, a serotonin receptor antagonist (S2), lowered blood pressure in patients with essential hypertension; at three months 72% (13/18) had a successful reduction in pressure." | 9.06 | Comparison of ketanserin and metoprolol in the treatment of essential hypertension. ( Agerter, DC; Araas, FJ; Collins, JB; Fisher, LD; Schirger, A; Sheps, SG; Spiekerman, RE; Zachariah, PK, 1987) |
| "Forty adult patients, who developed postoperative hypertension (greater than 160/90 mm Hg) following major abdominal surgery were given double-blind, randomized either ketanserin 10 mg i." | 9.06 | The influence of ketanserin, droperidol and hydergine on postoperative hypertension during early recovery following major abdominal surgery. ( Anger, C; Hoch, D; Lawin, P; Van Aken, H, 1987) |
| "17 subjects with essential hypertension (14 male, 3 female - ages: 40-69 years), 13 of whom continued their previous anti-hypertensive therapy, completed a double-blind cross-over trial of ketanserin 40 mg twice daily versus placebo tablets twice daily - each treatment phase was six weeks in duration." | 9.05 | The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1984) |
| "Ketanserin, a new 5-hydroxy-tryptamine antagonist, was given at three different dosage levels (double-blind, randomized) in a dose finding study for 2 months to 31 patients with mild to moderately severe essential hypertension." | 9.05 | Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1983) |
| "Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double blind crossover protocol, each treatment period lasting six weeks." | 9.05 | Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. ( Amery, A; de Schaepdryver, A; Fagard, R; Fiocchi, R; Lijnen, P; Moerman, E; Staessen, J, 1984) |
| "We investigated the effect of peripheral serotonin receptor blockade on preeclamptic hypertension in 20 postpartum patients by the use of ketanserin, a serotonin receptor antagonist." | 9.05 | Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist. ( Socol, ML; Vaisrub, N; Weiner, CP, 1984) |
| "Ketanserin, a 5-HT type 2 receptor antagonist, was administered intravenously to nine patients with essential hypertension in a double-blind placebo controlled study to investigate the drug's effects on blood pressure, heart rate, the renin-angiotensin system and sympatho-adrenal function." | 9.05 | Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension. ( Ball, SG; Fraser, R; Inglis, GC; Isles, CG; Murray, GD; Robertson, JI; Zabludowski, JR; Zoccali, C, 1984) |
| "Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double-blind crossover protocol, each treatment period lasting 6 weeks." | 9.05 | Hemodynamic response to chronic ketanserin treatment in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; Staessen, J, 1985) |
| "Seventeen subjects with essential hypertension (14 men, 3 women, 40-69 years of age), 13 of whom continued their previous antihypertensive therapy, completed a double-blind crossover trial of ketanserin 40 mg twice daily versus placebo tablets twice daily." | 9.05 | Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1985) |
| " Since ketanserin, a more specific 5-HT2-serotoninergic (5-HT2) antagonist, has been shown to affect aldosterone secretion in essential hypertension, we have further investigated this mechanism by injecting ketanserin (10 mg i." | 9.05 | Effect of ketanserin in primary aldosteronism. ( Armanini, D; Boscaro, M; D'Agostino, D; Mantero, F; Opocher, G; Rocco, S, 1985) |
| "Ketanserin, an investigational, antiserotonergic agent, at a dose of 40 mg bid was given to 18 patients with mild to moderate primary hypertension in a randomized, double-blind, crossover study, with 100-mg metoprolol bid for four weeks each." | 9.05 | Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. ( Fasano, ML; Ferrara, LA; Iannuzzi, A; Rubba, P; Soro, S, 1985) |
| "The antihypertensive effect of the selective serotonin antagonist ketanserin was examined in a double-blind, placebo-controlled, parallel group study in 20 patients with essential hypertension." | 9.05 | Ketanserin in essential hypertension: a double-blind, placebo-controlled study. ( Cameron, HA; Ramsay, LE, 1985) |
| "After completion of this article, the reader will be able to list the various drugs and their associated side effects that are used to treat hypertensive disorders during pregnancy; to describe the various effects of serotonin on the cardiovascular system; to summarize the literature concerning the use of ketanserin during pregnancy; and to list the potential uses of ketanserin in this setting." | 8.80 | Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin. ( Odendaal, HJ; Steyn, DW, 2000) |
| "Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension." | 8.78 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. ( Brogden, RN; Sorkin, EM, 1990) |
| "The rationale for ketanserin therapy in hypertension is reviewed against the background of known physiological and pathophysiological effects of serotonin." | 8.77 | The rationale for ketanserin therapy in hypertension. ( Hansson, L; Hedner, T, 1987) |
| "The hemodynamic changes caused by ketanserin, an anti-hypertensive agent with S2-serotonergic receptor and alpha 1-adrenoceptor blocking properties, are reviewed in patients with essential hypertension." | 8.77 | Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man. ( Fournier, V; Laurent, S; Pannier, B; Safar, ME; Weiss, YA, 1987) |
| "We assess the effects of ipsapirone (a 5-HT1A receptor agonist), ketanserin (a 5-HT2A receptor antagonist), (-)-pindolol (a 5-HT1A receptor antagonist), and DOI (a 5-HT2A receptor agonist) on heatstroke in a rat model." | 7.73 | Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke. ( Chang, CP; Chen, SH; Lin, MT, 2005) |
| "The above study was undertaken in order to demonstrate the efficacy of ketanserin in mild to moderate essential arterial hypertension." | 7.68 | [Effectiveness of ketanserin in the treatment of light-to-moderate arterial hypertension]. ( Azzaretti, G; Bressan, MA; Daglio, M; Fogari, R; Poggio, M; Poletti, L; Ripamonti, L; Vlacos, D, 1993) |
| "The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension." | 7.68 | Absence of effects of ketanserin on renal prostacyclin and thromboxane A2 in essential hypertension. ( Gambini, G; Rossi, S; Valori, C, 1991) |
| "The authors report the case of an 84-year-old man with mild aortic valvular disease and arterial hypertension who developed marked QT interval prolongation and several lipotimic and syncopal attacks after 3 months of treatment with ketanserin (40 mg/day)." | 7.68 | [Prolongation of the QT interval and torsade de pointes caused by ketanserin]. ( Arfiero, S; Ometto, R; Vincenzi, M, 1990) |
| "Ten patients with essential hypertension and normal renal function were treated with ketanserin (20-40 mg twice a day), administered for 8 weeks." | 7.68 | Antihypertensive therapy with ketanserin: effects on central and renal hemodynamics, and microalbuminuria. ( Bedogna, V; Casagrande, P; Giorgetti, P; Graziani, MS; Loschiavo, C; Maschio, G; Valvo, E, 1990) |
| "Ketanserin is a serotonin (S2) blocker that reduces blood pressure (BP) in patients with essential hypertension preferentially by a reduction of peripheral vascular resistance." | 7.67 | A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. ( Berglund, G; Hedner, T; Persson, B, 1985) |
| "This study assesses the efficacy, safety, and dose-response curve of ketanserin, according to parenteral routes of administration, in the treatment of acute severe essential hypertension." | 7.67 | Ketanserin in parenteral treatment of acute essential hypertension: a dose-response curve. ( Lemus, J; Lucioni, MC; Milei, J; Schiavone, M, 1987) |
| "The principal aim of this study was to investigate the effects of ketanserin on peripheral vascular pressor mechanisms in nine patients with essential hypertension, including an assessment of the responsiveness to intravenous infusions of the alpha 1-adrenergic agonist, phenylephrine, and the nonadrenergic vasoconstrictor, angiotensin II." | 7.67 | Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension. ( Donnelly, R; Elliott, HL; Reid, JL, 1988) |
| "The antihypertensive effect of ketanserin, a recent 5-hydroxytryptamine (5-HT) antagonist, which acts on the 5-HT2-subtype receptor, was evaluated in 10 patients of both sexes (age range 35-69 years) with mild to moderate essential hypertension." | 7.67 | [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension]. ( Fioroni, E; Gambini, G; Gradoli, C; Pinchi, G; Proietti, MG; Valori, C, 1989) |
| "This study was carried out to investigate the hypotensive mechanisms of ketanserin and Ca-antagonists (verapamil and diltiazem) in hypertension." | 7.67 | Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K, 1989) |
| "This study was performed to investigate whether ketanserin (a serotonergic receptor antagonist) might affect the sympathetic nerve activity in resistance vessels of hypertension." | 7.67 | Ketanserin decreases sympathetic nervous activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K; Tsuda, S, 1988) |
| "The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) administration of ketanserin, have been investigated in a single blind study of 10 patients with uncomplicated mild hypertension." | 7.67 | Pharmacokinetics of ketanserin in patients with essential hypertension. ( Hedner, T; Persson, B; Pettersson, A, 1987) |
| "Two patients developed profound hypotension approximately one hour after taking an initial oral dose of ketanserin 40 mg." | 7.67 | Profound hypotension after the first dose of ketanserin. ( Cameron, HA; Ramsay, LE; Waller, PC, 1987) |
| "In patients developing hypertension following coronary artery bypass surgery (CABG) the possible role of 5-hydroxytryptamine (5-HT; serotonin) was investigated by injecting ketanserin, a specific 5-HT2-receptor antagonist." | 7.66 | The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. ( Kolling, JB; Reneman, RS; Scheijgrond, HW; van der Starre, PJ, 1983) |
| "The possible role of 5-hydroxytryptamine (serotonin) in patients developing hypertension following coronary artery bypass surgery was investigated by intravenous administration of ketanserin, a specific 5-hydroxytryptamine-receptor antagonist." | 7.66 | Ketanserin in the treatment of hypertension following coronary artery bypass surgery. A preliminary study. ( De Wet, JI; Diedericks, BJ; Roelofse, JA, 1983) |
| "Blood pressure and heart rate, supine and standing, were studied in patients with essential hypertension during 8 weeks of oral therapy with two dosage schedules of ketanserin, 40 mg once and twice daily." | 7.66 | Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. ( Berglund, G; Hedner, T; Persson, B, 1983) |
| "The long-term haemodynamic effects of ketanserin, a new serotonin-antagonist, was examined in 13 patients of both sexes (age range 24-62 years) with mild and moderate essential hypertension (EH)." | 7.66 | Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| "The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension." | 7.66 | Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. ( Boomsma, F; Man in 't Veld, AJ; Schalekamp, MA; Wenting, GJ; Woittiez, AJ, 1982) |
| " Dosage in excess of 60 mg of Kn per day caused troublesome central nervous system symptoms or headache in some patients." | 6.66 | Clinical studies with ketanserin in hypertension. ( Brown, SA; Simpson, FO; Spears, GF; Waal-Manning, HJ, 1985) |
| " The twice daily dosage schedule caused trough blood pressure control with both drugs." | 6.66 | Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. ( Alcocer, L; Copertari, P; Feruglio, F; Landi, E; Lopes, M; San Martin, C; Zin, C, 1987) |
| " The dosage of ketanserin (K) was 20 mg b." | 6.66 | Multicenter study with ketanserin in essential hypertension: an Argentine experiment. ( Bernardiner, E; Demartini, A; Genta, C; Gypen, L; Pezzano, R; Scheijgrond, H; Torres, J, 1987) |
| "Ketanserin is a novel agent that has been shown to be a specific 5-HT2-serotonergic antagonist." | 6.66 | Renal hemodynamic effects of ketanserin therapy in essential hypertension. ( Gonzalez, DG; Henderson, JD; Kaplan, NM; Lugo, CE; Ralakis, JM; Ram, CV; Zachariah, N, 1987) |
| " The rise in blood pressure between 2 and 14 h after dosing was 11/4 mm Hg supine (P less than 0." | 6.66 | Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. ( Cameron, HA; Ramsay, LE; Waller, PC, 1987) |
| " in combination with a beta-adrenergic blocking agent or a diuretic was assessed in an open study in 35 patients with essential hypertension, who had not responded to treatment with beta-blockers, diuretics or their combination." | 6.66 | Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study. ( Bartoloni, C; Dupont, P; Feltkamp, H; Johnston, CI; Kaindl, F; Steinbach, K; Zilcher, H, 1988) |
| "Ketanserin appears to be a new alternative approach in the treatment of mild and moderate essential hypertension." | 6.66 | Ketanserin versus metoprolol in the treatment of essential hypertension. ( Bernardiner, E; Lemus, J; Milei, J, 1986) |
| "Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors." | 6.66 | Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. ( Abrignani, MG; Adamo, L; Alaimo, G; Avellone, G; Cutietta, A; Giordano, U; Indovina, A; Novo, S; Pinto, A; Strano, A, 1986) |
| "Essential hypertension is a multifactorial disorder mediated by multiple mechanisms." | 6.66 | Ketanserin in essential hypertension. Effects of blood pressure on renal hemodynamics. ( Ram, CV, 1988) |
| "Ketanserin is a S2-serotonergic receptor antagonist with antihypertensive activity." | 6.66 | Ketanserin in the treatment of diabetes-associated hypertension. ( Beretta-Piccoli, C, 1988) |
| "Ketanserin is a serotonin S2 receptor antagonist with antihypertensive activity." | 6.66 | Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension. ( Bachmann, C; Beretta-Piccoli, C; Riesen, W; Salvadé, G; Zuppinger, K, 1988) |
| "Two double-blind multicenter trials were performed to compare the antihypertensive action of ketanserin, at an oral dosage of 20 mg three times daily, with that of placebo over a period of four to six weeks." | 6.66 | Double-blind comparison of ketanserin with placebo in patients with essential hypertension. ( Baeten, B; Peeters, G; Sieben, G; Symoens, J; Wellens, D, 1986) |
| "Ketanserin was given 40 mg twice daily to 10 hypertensive patients during 4 weeks in a double-blind placebo-controlled trial." | 6.65 | Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. ( Hedner, T; Persson, B, 1984) |
| "Ketanserin is a new, specific serotonin receptor blocking agent, which causes vasodilatation, presumably by an action on the vascular wall." | 6.65 | Ketanserin in essential hypertension: effects during rest and exercise. ( Berglund, G; Hedner, T; Persson, B, 1983) |
| "Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-hydroxytryptamine, 5HT) receptors of the 5HT2 subtype." | 6.37 | Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. ( Hedner, T; Persson, B, 1988) |
| "Ketanserin is a selective S2-serotoninergic antagonist with additional alpha 1-adrenergic blocking properties." | 6.37 | Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. ( Amery, A; Birkenhäger, W; Breckenridge, A; Bühler, F; Distler, A; Dormandy, J; Doyle, A; Frohlich, E; Hansson, L; Vanhoutte, P, 1988) |
| "Ketanserin is a specific S2 serotonergic receptor blocker with possible adrenergic blocking activities that has clinical utility in the treatment of hypertension." | 6.37 | Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin. ( Frishman, WH; Huberfeld, S; Okin, S, 1988) |
| "The available data on the use of ketanserin in diabetes mellitus have been reviewed." | 6.16 | Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review. ( Janssens, M; Robertson, MP; Symoens, J, 1991) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94." | 5.28 | Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. ( Konishi, M; Sakakura, M; Tsushima, N, 1990) |
| "Prazosin pretreatment and TAB prevented these effects." | 5.27 | Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin. ( Angus, JA; Wright, CE, 1983) |
| "Ketanserin is a serotonin antagonist with high affinity for S2-serotonergic receptors, which mediate the vasoconstrictor effects of serotonin." | 5.27 | Ketanserin: a possible tool for studying the role of serotonin in hypertension. ( Boomsma, F; Man in't Veld, AJ; Schalekamp, MA; Wenting, GJ; Woittiez, AJ, 1985) |
| "Ketanserin is a 5-HT2 antagonist with alpha-adrenoreceptor blocking activity." | 5.27 | Ketanserin in the acute management of severe hypertension. ( Kincaid-Smith, P; Murphy, BF; Whitworth, JA, 1985) |
| "Twenty-seven patients with untreated hypertension and/or intermittent claudication received a bolus intravenous (i." | 5.27 | Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. ( Freitag, B; Pointel, JP; Schmitt, C; Stoltz, JF; Voisin, P; Zannad, F, 1985) |
| "Ketanserin was given alone, 40 mg o." | 5.27 | Treatment of arterial hypertension with ketanserin in mono- and combination therapy. ( Berglund, G; Hedner, T; Persson, B; Pettersson, A, 1985) |
| "Ketanserin is a pure antagonist of serotonin S2-receptors, in blood vessels, platelets and bronchial tissue." | 5.27 | Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism. ( Assogna, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Lais, A; Pisculli, M; Romeo, M; Valgiusti, FC, 1986) |
| "Ketanserin was administered intravenously as either 20 or 10 mg boluses to 16 patients with severe preeclampsia in labor." | 5.27 | Intrapartum treatment of preeclamptic hypertension by ketanserin. ( Hulme, VA; Odendaal, HJ, 1986) |
| "Ketanserin treatment administered over a period of 8 weeks, decreased arterial pressure in patients with essential hypertension and, to a lesser extent, in diabetics, but not in normal subjects." | 5.27 | Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension. ( Beretta-Piccoli, C; Waser, M; Ziegler, WH, 1988) |
| "Determine the definitive position of ketanserin and dihydralazine for treatment of severe hypertension in pregnancy." | 5.20 | Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. ( Bijvank, SW; Duvekot, JJ; Edens, MA; Hanff, LM; Roofthooft, DW; Steegers, EA; Visser, W; Vulto, AG, 2015) |
| "Ketanserin is an antihypertensive drug that is increasingly being used parenterally in the treatment of pre-eclampsia." | 5.11 | Population pharmacokinetics of ketanserin in pre-eclamptic patients and its association with antihypertensive response. ( Hanff, LM; Steegers, EA; Visser, W; Vulto, AG, 2005) |
| "To establish the optimal dosage of ketanserin in the treatment of severe hypertension in pregnancy." | 5.10 | The optimal dosage of ketanserin for patients with severe hypertension in pregnancy. ( de Jeu, RM; Odendaal, HJ; Steyn, DW; van Geijn, HP; van Schie, DL, 2002) |
| "The aim of the study was to compare antihypertensive efficacy and safety of ketanserin with those of enalapril in the treatment of hypertension." | 5.08 | [Cross-over study on the effects of ketanserin vs enalapril in the treatment of hypertension]. ( Guerini Rocco, C; Modica, G; Monte, I, 1995) |
| "The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients." | 5.08 | Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic-hyperinsulinemic clamp technique. ( Derosa, G; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1995) |
| "When hypertension (defined as mean arterial pressure > 85 mmHg) developed within the first 2 hours after arrival in the intensive care unit, patients received urapidil (n = 62) or ketanserin (n = 60) to reach a mean arterial pressure between 65 and 75 mmHg." | 5.08 | A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery. ( Kal, JE; Kooyman, J; Korsten, HH; Langemeijer, JJ; Porsius, M; van den Ende, R; van der Starre, PJ; van der Stroom, JG; van Wezel, HB; van Zwieten, PA, 1997) |
| "We found an association between the addition of ketanserin to aspirin and a decrease in the number of cases of pre-eclampsia and severe hypertension, as well as improved pregnancy outcome among patients with mild to moderate midtrimester hypertension." | 5.08 | Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. ( Odendaal, HJ; Steyn, DW, 1997) |
| " The need for delivery for fetal distress did not differ (3 after dihydralazine, 1 after ketanserin, P = 0." | 5.08 | Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. ( Odendaal, HJ; Steyn, DW, 1997) |
| "To compare the haemodynamic efficacy of ketanserin (a selective serotonin2-receptor blocker) with dihydralazine in the management of severe early-onset hypertension in pregnancy." | 5.08 | The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy. ( Bolte, AC; Dekker, GA; Strack van Schijndel, RJ; van Eyck, J; van Geijn, HP, 1998) |
| "Ketanserin, a serotonin-2-receptor antagonist, was administered to 16 patients with mild to moderate essential hypertension in randomized single-blind placebo controlled study." | 5.07 | [Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension]. ( Berent, H; Brym, E; Czerniewska, E; Januszewicz, W; Knypl, K; Kuçzyńska, K; Wacławek-Maczkowska, J; Wasowska, T; Wocial, B, 1993) |
| "The response of arterial BP and intracranial pressure to an intravenous injection of the serotonin antagonist, ketanserin, was recorded in ten patients with hypertension following intracerebral haemorrhage." | 5.07 | Effect of intravenous ketanserin on arterial and intracranial pressures in patients with systemic hypertension following intracerebral haemorrhage. ( Kay, R; Nicholls, MG; Poon, WS, 1993) |
| "In 51 patients with stage II essential hypertension (mild and moderate arterial hypertension), a cross-over study was carried out to estimate the efficacy of the use of ketanserin (KS), an antagonist of serotonin receptors, as compared to the efficacy of placebo, the beta-adrenoblocker propranolol (PP), the diuretic triampur and the beta 1-adrenoblocker prazosin." | 5.07 | [A cross-over study of ketanserin compared to placebo, beta-adrenergic blockader, diuretic and alpha 1-adrenergic blockader. Cooperative research in the USSR (the Cooperative Program to Study New Preparations in the Prevention of Arterial Hypertension). W ( Filatova, NP; Metelitsa, VI, 1991) |
| "The efficacy of ketanserin treatment (40 mg daily for 90 days) was evaluated in 88 patients with arterial hypertension combined with Leriche-Fontaine stage II obliterating arterial disease of the lower limbs." | 5.07 | [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin]. ( Mollo, P, 1991) |
| "The effect of ketanserin at 5 mg, 10 mg and 20 mg twice daily for 3 months was studied in Chinese patients with hypertension." | 5.07 | Ketanserin in the treatment of hypertension: a multicentre dose-finding study in China. ( Huang, DX; Liu, GS; Peng, SY; Tang, XL; Tong, YZ; Wang, SR; Xing, JL; Yang, XS, 1991) |
| "Efficacy and safety of ketanserin was studied prospectively in a randomized and double-blind trial involving 221 patients treated for hypertension and/or coronary artery disease." | 5.06 | Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group. ( Geibel, A; Hartung, J; Hohnloser, S; Just, H; Meinertz, T; Seiler, KU; Zehender, M, 1990) |
| "Forty patients with mild-to-moderate arterial hypertension were randomized for double-blind treatment with ketanserin (20 mg b." | 5.06 | [Short and medium term evaluation of captopril-ketanserin combination in mild to moderate arterial hypertension]. ( Barbara, C; Bruzzone, F; Canale, C; Masperone, MA; Provinciali, L; Romeo, M; Terrachini, V; Zanna, C, 1990) |
| "The effects of ketanserin, 40 mg/day (KE40) and 80 mg/day (KE80) on mean arterial pressure, lipids, lipoproteins, and circulating atrial natriuretic factor (ANF) were investigated in a 24-week controlled study in 29 patients suffering from mild to moderate hypertension." | 5.06 | Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension. ( Bielmann, P; Davignon, J; Gutkowska, J; Leduc, G, 1990) |
| "To assess the role of the serotonin antagonist ketanserin in the management of hypertension in the elderly, 12 patients with a mean age of 68 years (range 60-79 years) were treated with ketanserin in a randomised double-blind placebo-controlled cross-over trial." | 5.06 | The antihypertensive efficacy of ketanserin in the elderly evaluated by ambulatory blood pressure measurement. ( Atkins, N; Cox, JP; Marron, J; McCormack, PM; Mee, F; O'Brien, E; O'Malley, K, 1990) |
| "Thirty patients who developed arterial hypertension following coronary artery bypass grafting, despite sedation, were treated randomly with sodium nitroprusside (SNP), ketanserin or urapidil." | 5.06 | Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting. ( Lauwers, P; Möllhoff, T; Mulier, JP; Müller, E; Van Aken, H, 1990) |
| "Ketanserin, the specific S2 serotonin antagonist, is undergoing evaluation for the therapy of hypertension of all degrees of severity." | 5.06 | Effects of intravenous ketanserin on severely hypertensive patients with double-blind crossover assessment of central side-effects. ( Jennings, AA; Opie, LH, 1987) |
| "In order to assess the medium-term efficacy of ketanserin in comparison with that of the beta-blocker, propranolol, a randomized double-blind crossover trial was conducted involving 13 patients suffering from mild or moderate essential hypertension." | 5.06 | Ketanserin versus propranolol in the treatment of mild and moderate essential hypertension: corroboration with ambulatory blood pressure monitoring. ( Alaimo, G; Giordano, U; Novo, S; Raineri, A; Strano, A, 1987) |
| "In the Swiss Ketanserin Study the antihypertensive efficacy and tolerability of ketanserin (given in 20 or 40 mg doses twice daily) was investigated, after a placebo run-in phase, as monotherapy (n = 68) as well as in combination with either atenolol (100 mg/day) (n = 30) or the potassium-sparing diuretic hydrochlorothiazide (50 mg/day) and amiloride (5 mg/day) (n = 26) in 124 patients with essential hypertension, aged 41 to 82 years." | 5.06 | Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Solèr, M; Vallotton, M, 1987) |
| "The antihypertensive effect of the combination of ketanserin, a new antiserotonergic agent, and thiazide has been evaluated in 35 patients with arterial hypertension of mild to moderate degree in the greater than 50-year-old age group." | 5.06 | Antihypertensive efficacy of the combination of ketanserin + thiazide in hypertensives older than 50 years. ( Fasano, ML; Ferrara, LA; Mancini, M; Pasanisi, F; Soro, S, 1987) |
| "The effects of monotherapy with once-daily ketanserin (40 mg) were compared to those of ketanserin (40 mg) plus hydrochlorothiazide (25 mg) once daily in 21 patients with mild essential hypertension." | 5.06 | Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily. ( Leary, WP; Maharaj, B; Reyes, AJ; van der Byl, K, 1987) |
| "We have studied the acute effects of the serotonergic type-2 (5-HT2) antagonists ketanserin and ritanserin given as single oral doses to patients with essential hypertension." | 5.06 | Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. ( Ball, SG; Hosie, J; Robertson, JI; Stott, DJ, 1987) |
| "In patients with essential hypertension, ketanserin (40 mg once or twice daily) reduces the blood pressure in mono- and combination therapy." | 5.06 | Experience with ketanserin and ritanserin in hypertensive patients. ( Hedner, T; Persson, B, 1988) |
| "Ketanserin, a serotonin-2-receptor antagonist, was administered to 12 subjects with mild to moderate hypertension in a randomized, double-blind, placebo-controlled crossover trial." | 5.06 | Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects. ( Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988) |
| "Efficacy and safety of ketanserin were studied prospectively in a randomized, double-blind trial involving 221 patients treated for hypertension or coronary artery disease, or both." | 5.06 | Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. ( Geibel, A; Hartung, J; Hohnloser, S; Just, H; Meinertz, T; Seiler, KU; Zehender, M, 1989) |
| "The antihypertensive effect of a recently introduced antiserotoninic drug, ketanserin, was examined in a single-blind, placebo-controlled parallel group study in 28 patients with mild to moderate hypertension." | 5.06 | Clinical investigation of the effect of ketanserin: a new antihypertensive drug. ( Cacciatore, L; Cocozza, M; Coto, F; Coto, V; Lucariello, A; Oliviero, U; Picano, T, 1989) |
| "Twenty patients requiring management of postoperative arterial hypertension following coronary artery bypass grafting (CABG) were randomly treated with either ketanserin (n = 10) or sodium nitroprusside (SNP) (n = 10)." | 5.06 | [Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation]. ( Lauwers, P; Möllhoff, T; Mulier, JP; Müller, E; Van Aken, H, 1989) |
| "Sixty patients, with mild to moderate essential hypertension, were considered for a double-blind trial comparing the effects of ketanserin and atenolol." | 5.06 | A double-blind comparative study of ketanserin with atenolol in essential hypertension. ( Andreoni, A; Antonicelli, R; Gambini, C; Paciaroni, E; Saccomanno, G, 1989) |
| "The antihypertensive efficacy and tolerability of the 5HT2-receptor antagonist ketanserin was investigated in 188 patients aged 41 to 82 years with mild to moderate essential hypertension." | 5.06 | [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy]. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Reutter, F; Vallotton, MB, 1989) |
| "The effects of ketanserin on blood pressure and well-being were investigated in 188 patients, aged 41-82 years, with mild to moderate essential hypertension." | 5.06 | Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Heer, K; Reutter, F; Vallotton, MB, 1989) |
| "The haemodynamic effects of ketanserin, a compound with S2-serotonergic receptor and alpha 1-adrenoceptor blocking properties, are reviewed in patients with essential hypertension." | 5.06 | Ketanserin: haemodynamic effects and mechanism of action. ( Man in 't Veld, AJ; Schalekamp, MA; van den Meiracker, AH; Wenting, GJ; Woittiez, AJ, 1986) |
| "The purpose of this study was to compare the effects of the serotonin antagonist ketanserin and the post-synaptic alpha-blocker prazosin on blood pressure in patients with essential hypertension." | 5.06 | Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker. ( Fisher, R; Gruebel, B; Koehle, W; Rosenthal, J, 1986) |
| " Ketanserin or slow-release nifedipine were added to the treatment of 24 patients with hypertension uncontrolled by a thiazide diuretic plus beta-adrenoceptor antagonist in an observer-blind, randomised parallel-group study of 6 months duration." | 5.06 | Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker. ( Ramsay, LE; Solomon, SA; Waller, PC, 1987) |
| "The safety and efficacy of ketanserin, a competitive serotonin blocking agent, and propranolol were compared in 33 patients with mild to moderate hypertension (sitting diastolic blood pressure [DBP] 95-115 mm Hg) using a placebo run-in, randomized, double-blind parallel study design." | 5.06 | Serotonergic blockade compared with beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin with propranolol. ( Charlap, S; Frishman, WH; Greenberg, S; Huberfeld, SI; Laifer, L; Lapsker, J; Okin, S; Soberman, J; Strom, JA, 1988) |
| " A trial was carried out on medium-term treatment with ketanserin or propranolol in subjects suffering from mild to moderate hypertension." | 5.06 | Effects of ketanserin on ambulatory blood pressure monitoring in patients with essential hypertension. ( Abrignani, MG; Alaimo, G; Cutietta, A; Novo, S; Raineri, A; Strano, A, 1986) |
| "The antihypertensive effects of ketanserin (40 mg twice daily) and pindolol (5 mg twice daily) as monotherapy were compared in a crossover, double-blind trial in 17 patients with essential hypertension." | 5.06 | Comparison of ketanserin and pindolol in hypertension. ( Gordin, A; Saraste, K; Sundberg, S; Turanlahti, M, 1986) |
| "The long-term safety and efficacy of ketanserin in the treatment of essential hypertension was assessed in monotherapy or in combination with the beta-blocker, metoprolol." | 5.06 | Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol. ( Mauersberger, H, 1986) |
| "Ketanserin (K), a selective and specific S2-receptor antagonist, has been compared with metoprolol (M), a cardioselective beta-blocker, in a double-blind study in order to assess its efficacy and safety in the treatment of essential hypertension." | 5.06 | Clinical experience with ketanserin in the treatment of hypertension. ( Assogna, G; Costantini, C; del Rosso, G; Libretti, A; Mara, G; Palermo, A; Pizza, N, 1986) |
| "5 years) with mild hypertension were considered for a double-blind trial comparing the effects of ketanserin and propranolol." | 5.06 | Ketanserin in the treatment of mild hypertension in elderly patients: preliminary results of a controlled double-blind trial. ( Dona, G; Ribeiro, A; Tammaro, AE, 1986) |
| "Pharmacokinetic and antihypertensive effects of the S2-serotonergic antagonist ketanserin were determined in 10 patients with essential hypertension (WHO stages I-II) after a single intravenous (0." | 5.06 | Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients. ( Hedner, T; Persson, B; Pettersson, A, 1986) |
| "A randomized crossover trial was conducted in 15 patients with essential hypertension to compare the actions of prazosin, a specific alpha 1-adrenoceptor blocker, and ketanserin, an antagonist at alpha 1-adrenergic and serotonin receptors." | 5.06 | Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects. ( Marwood, JF; Mennie, BA; Stokes, GS, 1986) |
| "To clarify the antihypertensive effect, safety and clinical usefulness of ketanserin, a comparative double-blind study was carried out in 277 patients with essential hypertension using propranolol as a control drug." | 5.06 | Comparative double-blind study of ketanserin versus propranolol in the treatment of essential hypertension. ( Iimura, O; Ikeda, M; Ishii, M; Ito, K; Kaneko, Y; Masuyama, Y; Mizuno, Y; Omae, T; Takeda, T; Yoshinaga, K, 1988) |
| " The effect of ketanserin tartrate (20 to 60 mg daily), a new antihypertensive drug, on blood lipids was evaluated in a 12-week non-comparative clinical trial in 34 patients with mild or moderate hypertension." | 5.06 | Effects of ketanserin tartrate on serum lipids in patients with essential hypertension. ( Hirata, F; Homma, Y; Ishikawa, T; Mizuno, M; Nakamura, H; Nakaya, N; Saito, E; Tada, N; Takeuchi, I; Yasugi, T, 1988) |
| "The antihypertensive effects of the 5-HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension." | 5.06 | Antihypertensive response to ketanserin: influence of race and weight. ( Cressman, MD; Ferguson, RK; Gabos, C; Kosoglou, T; Rocci, ML; Vlasses, PH, 1988) |
| " In nine patients with essential hypertension, following single and multiple doses of ketanserin, assessments were made of blood pressure and heart rate, QT interval, and pressor responses to phenylephrine and angiotensin II." | 5.06 | Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "Ketanserin, a serotonin-2-receptor antagonist, was administered to 12 subjects with mild to moderate hypertension in a randomized, double-blind, placebo-controlled crossover trial." | 5.06 | Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin. ( Brewer, HB; Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988) |
| "Thirteen men, age 60 +/- 2 years (mean +/- SEM) with mild hypertension, 151 +/- 4/95 +/- 3 mm Hg, completed a randomized, double-blind, placebo-controlled crossover trial of ketanserin therapy." | 5.06 | Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. ( Campbell, R; Conlon, ME; Egan, B; Julius, S; Schork, N; Zwiefler, A, 1988) |
| "The antihypertensive effectiveness of a combination of ketanserin 20 mg plus hydrochlorothiazide 25 mg has been evaluated in 20 patients with arterial hypertension of mild to moderate degree in the age group over 50 years (age range 50-78 years)." | 5.06 | Blood pressure during a combination of ketanserin and hydrochlorothiazide. ( Celentano, E; Farinaro, E; Fasano, ML; Ferrara, LA; Mancini, M; Soro, S, 1987) |
| "Monotherapy with Ketanserin, a serotonin receptor antagonist, reduces blood pressure in a sizeable number of patients with essential hypertension." | 5.06 | Ketanserin in the treatment of essential hypertension. A double-blind study against metoprolol and a further long-term open treatment. ( Bernardiner, E; Lemus, J; Milei, J, 1986) |
| "Ketanserin, a serotonin receptor antagonist (S2), lowered blood pressure in patients with essential hypertension; at three months 72% (13/18) had a successful reduction in pressure." | 5.06 | Comparison of ketanserin and metoprolol in the treatment of essential hypertension. ( Agerter, DC; Araas, FJ; Collins, JB; Fisher, LD; Schirger, A; Sheps, SG; Spiekerman, RE; Zachariah, PK, 1987) |
| "Forty adult patients, who developed postoperative hypertension (greater than 160/90 mm Hg) following major abdominal surgery were given double-blind, randomized either ketanserin 10 mg i." | 5.06 | The influence of ketanserin, droperidol and hydergine on postoperative hypertension during early recovery following major abdominal surgery. ( Anger, C; Hoch, D; Lawin, P; Van Aken, H, 1987) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "17 subjects with essential hypertension (14 male, 3 female - ages: 40-69 years), 13 of whom continued their previous anti-hypertensive therapy, completed a double-blind cross-over trial of ketanserin 40 mg twice daily versus placebo tablets twice daily - each treatment phase was six weeks in duration." | 5.05 | The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1984) |
| "Ketanserin, a new 5-hydroxy-tryptamine antagonist, was given at three different dosage levels (double-blind, randomized) in a dose finding study for 2 months to 31 patients with mild to moderately severe essential hypertension." | 5.05 | Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1983) |
| "Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double blind crossover protocol, each treatment period lasting six weeks." | 5.05 | Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. ( Amery, A; de Schaepdryver, A; Fagard, R; Fiocchi, R; Lijnen, P; Moerman, E; Staessen, J, 1984) |
| "We investigated the effect of peripheral serotonin receptor blockade on preeclamptic hypertension in 20 postpartum patients by the use of ketanserin, a serotonin receptor antagonist." | 5.05 | Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist. ( Socol, ML; Vaisrub, N; Weiner, CP, 1984) |
| "Ketanserin, a 5-HT type 2 receptor antagonist, was administered intravenously to nine patients with essential hypertension in a double-blind placebo controlled study to investigate the drug's effects on blood pressure, heart rate, the renin-angiotensin system and sympatho-adrenal function." | 5.05 | Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension. ( Ball, SG; Fraser, R; Inglis, GC; Isles, CG; Murray, GD; Robertson, JI; Zabludowski, JR; Zoccali, C, 1984) |
| "Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double-blind crossover protocol, each treatment period lasting 6 weeks." | 5.05 | Hemodynamic response to chronic ketanserin treatment in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; Staessen, J, 1985) |
| "In 10 patients with primary arterial hypertension of mild or moderate degree, ketanserin, a competitive antagonist of serotonin receptors, was given for a period of 4 weeks, 40 mg twice daily." | 5.05 | Study with the competitive 5-HT2-serotonergic antagonist ketanserin. ( Fasano, ML; Ferrara, LA; Mancini, M; Marotta, G; Rubba, P; Soro, S, 1985) |
| "The antihypertensive effect of ketanserin in combination with beta-adrenergic blockade was assessed in a double-blind crossover (4 weeks) manner in 10 patients with essential hypertension." | 5.05 | Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents. ( Hedner, T; Persson, B, 1985) |
| "Seventeen subjects with essential hypertension (14 men, 3 women, 40-69 years of age), 13 of whom continued their previous antihypertensive therapy, completed a double-blind crossover trial of ketanserin 40 mg twice daily versus placebo tablets twice daily." | 5.05 | Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1985) |
| " Since ketanserin, a more specific 5-HT2-serotoninergic (5-HT2) antagonist, has been shown to affect aldosterone secretion in essential hypertension, we have further investigated this mechanism by injecting ketanserin (10 mg i." | 5.05 | Effect of ketanserin in primary aldosteronism. ( Armanini, D; Boscaro, M; D'Agostino, D; Mantero, F; Opocher, G; Rocco, S, 1985) |
| "Ketanserin, an investigational, antiserotonergic agent, at a dose of 40 mg bid was given to 18 patients with mild to moderate primary hypertension in a randomized, double-blind, crossover study, with 100-mg metoprolol bid for four weeks each." | 5.05 | Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. ( Fasano, ML; Ferrara, LA; Iannuzzi, A; Rubba, P; Soro, S, 1985) |
| "The antihypertensive effect of the selective serotonin antagonist ketanserin was examined in a double-blind, placebo-controlled, parallel group study in 20 patients with essential hypertension." | 5.05 | Ketanserin in essential hypertension: a double-blind, placebo-controlled study. ( Cameron, HA; Ramsay, LE, 1985) |
| "After completion of this article, the reader will be able to list the various drugs and their associated side effects that are used to treat hypertensive disorders during pregnancy; to describe the various effects of serotonin on the cardiovascular system; to summarize the literature concerning the use of ketanserin during pregnancy; and to list the potential uses of ketanserin in this setting." | 4.80 | Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin. ( Odendaal, HJ; Steyn, DW, 2000) |
| " Ketanserin is a highly selective S2-serotonergic antagonist with additional alpha-adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension." | 4.79 | Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. ( Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995) |
| "Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension." | 4.78 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. ( Brogden, RN; Sorkin, EM, 1990) |
| "The rationale for ketanserin therapy in hypertension is reviewed against the background of known physiological and pathophysiological effects of serotonin." | 4.77 | The rationale for ketanserin therapy in hypertension. ( Hansson, L; Hedner, T, 1987) |
| "The hemodynamic changes caused by ketanserin, an anti-hypertensive agent with S2-serotonergic receptor and alpha 1-adrenoceptor blocking properties, are reviewed in patients with essential hypertension." | 4.77 | Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man. ( Fournier, V; Laurent, S; Pannier, B; Safar, ME; Weiss, YA, 1987) |
| "We assess the effects of ipsapirone (a 5-HT1A receptor agonist), ketanserin (a 5-HT2A receptor antagonist), (-)-pindolol (a 5-HT1A receptor antagonist), and DOI (a 5-HT2A receptor agonist) on heatstroke in a rat model." | 3.73 | Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke. ( Chang, CP; Chen, SH; Lin, MT, 2005) |
| " The comparison was focus on hemodynamics, cardiovascular hypertrophy, and hemodynamic responses to ketanserin." | 3.72 | Comparative study of sinoaortic denervated rats and spontaneously hypertensive rats. ( Miao, CY; Su, DF; Yuan, WJ, 2003) |
| "The above study was undertaken in order to demonstrate the efficacy of ketanserin in mild to moderate essential arterial hypertension." | 3.68 | [Effectiveness of ketanserin in the treatment of light-to-moderate arterial hypertension]. ( Azzaretti, G; Bressan, MA; Daglio, M; Fogari, R; Poggio, M; Poletti, L; Ripamonti, L; Vlacos, D, 1993) |
| "Ketanserin and calcium antagonists are frequently used for the treatment of arterial hypertension in the elderly." | 3.68 | [Cardiac interactions between ketanserin and the calcium antagonist nifedipine]. ( Alberio, L; Beretta-Piccoli, C; Koch, P; Tanzi, F; Zehender, M, 1992) |
| "Eighteen dyslipidaemic patients affected with moderate hypertension were studied before and after short-term treatment with ketanserin (40 mg/die) on hypocaloric (22-25 kcal/kg/die) and normosodic-normopotassic diet." | 3.68 | Haemodynamic and metabolic effects of ketanserin in dyslipidaemic hypertensive subjects. ( Letizia, C; Scavo, D; Sellini, M, 1991) |
| "The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension." | 3.68 | Absence of effects of ketanserin on renal prostacyclin and thromboxane A2 in essential hypertension. ( Gambini, G; Rossi, S; Valori, C, 1991) |
| "The authors report the case of an 84-year-old man with mild aortic valvular disease and arterial hypertension who developed marked QT interval prolongation and several lipotimic and syncopal attacks after 3 months of treatment with ketanserin (40 mg/day)." | 3.68 | [Prolongation of the QT interval and torsade de pointes caused by ketanserin]. ( Arfiero, S; Ometto, R; Vincenzi, M, 1990) |
| "Ten patients with essential hypertension and normal renal function were treated with ketanserin (20-40 mg twice a day), administered for 8 weeks." | 3.68 | Antihypertensive therapy with ketanserin: effects on central and renal hemodynamics, and microalbuminuria. ( Bedogna, V; Casagrande, P; Giorgetti, P; Graziani, MS; Loschiavo, C; Maschio, G; Valvo, E, 1990) |
| "This study examined the effects of the serotonergic (5-HT2) antagonist ketanserin in sheep on haemodynamic responses to infused serotonin (5-HT), development of adrenocorticotrophin (ACTH)-induced hypertension, and the effect of ACTH on in vivo pressor responsiveness to 5-HT." | 3.67 | Serotonergic mechanisms and blood pressure in sheep. ( Coghlan, JP; Denton, DA; Mills, EH; Nelson, MA; Scoggins, BA; Spence, CD; Whitworth, JA, 1985) |
| "Ketanserin is a serotonin (S2) blocker that reduces blood pressure (BP) in patients with essential hypertension preferentially by a reduction of peripheral vascular resistance." | 3.67 | A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. ( Berglund, G; Hedner, T; Persson, B, 1985) |
| "This study assesses the efficacy, safety, and dose-response curve of ketanserin, according to parenteral routes of administration, in the treatment of acute severe essential hypertension." | 3.67 | Ketanserin in parenteral treatment of acute essential hypertension: a dose-response curve. ( Lemus, J; Lucioni, MC; Milei, J; Schiavone, M, 1987) |
| "The principal aim of this study was to investigate the effects of ketanserin on peripheral vascular pressor mechanisms in nine patients with essential hypertension, including an assessment of the responsiveness to intravenous infusions of the alpha 1-adrenergic agonist, phenylephrine, and the nonadrenergic vasoconstrictor, angiotensin II." | 3.67 | Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension. ( Donnelly, R; Elliott, HL; Reid, JL, 1988) |
| "Concentrations of serotonin and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in platelet rich plasma, the urinary 5-HIAA excretion rate, and serotonin-induced platelet aggregation were measured in 17 patients with essential hypertension before, and at the end of, 8 weeks of oral ketanserin therapy at 20 to 40 mg twice daily." | 3.67 | Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin. ( Amstein, R; Bühler, FR; Ferracin, F; Fetkovska, N; Pletscher, A, 1988) |
| "The antihypertensive effect of ketanserin, a recent 5-hydroxytryptamine (5-HT) antagonist, which acts on the 5-HT2-subtype receptor, was evaluated in 10 patients of both sexes (age range 35-69 years) with mild to moderate essential hypertension." | 3.67 | [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension]. ( Fioroni, E; Gambini, G; Gradoli, C; Pinchi, G; Proietti, MG; Valori, C, 1989) |
| "This study was carried out to investigate the hypotensive mechanisms of ketanserin and Ca-antagonists (verapamil and diltiazem) in hypertension." | 3.67 | Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K, 1989) |
| "The serotonin (S2) antagonist, ketanserin was given to 16 patients with essential hypertension on a single-blind basis." | 3.67 | Regional haemodynamics and antihypertensive effects during long-term ketanserin treatment. ( Andersson, O; Berglund, G; Hedner, T; Persson, B; Petterson, A, 1986) |
| "This study was performed to investigate whether ketanserin (a serotonergic receptor antagonist) might affect the sympathetic nerve activity in resistance vessels of hypertension." | 3.67 | Ketanserin decreases sympathetic nervous activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K; Tsuda, S, 1988) |
| "The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) administration of ketanserin, have been investigated in a single blind study of 10 patients with uncomplicated mild hypertension." | 3.67 | Pharmacokinetics of ketanserin in patients with essential hypertension. ( Hedner, T; Persson, B; Pettersson, A, 1987) |
| "Two patients developed profound hypotension approximately one hour after taking an initial oral dose of ketanserin 40 mg." | 3.67 | Profound hypotension after the first dose of ketanserin. ( Cameron, HA; Ramsay, LE; Waller, PC, 1987) |
| "In patients developing hypertension following coronary artery bypass surgery (CABG) the possible role of 5-hydroxytryptamine (5-HT; serotonin) was investigated by injecting ketanserin, a specific 5-HT2-receptor antagonist." | 3.66 | The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. ( Kolling, JB; Reneman, RS; Scheijgrond, HW; van der Starre, PJ, 1983) |
| "The possible role of 5-hydroxytryptamine (serotonin) in patients developing hypertension following coronary artery bypass surgery was investigated by intravenous administration of ketanserin, a specific 5-hydroxytryptamine-receptor antagonist." | 3.66 | Ketanserin in the treatment of hypertension following coronary artery bypass surgery. A preliminary study. ( De Wet, JI; Diedericks, BJ; Roelofse, JA, 1983) |
| "Blood pressure and heart rate, supine and standing, were studied in patients with essential hypertension during 8 weeks of oral therapy with two dosage schedules of ketanserin, 40 mg once and twice daily." | 3.66 | Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. ( Berglund, G; Hedner, T; Persson, B, 1983) |
| "The long-term haemodynamic effects of ketanserin, a new serotonin-antagonist, was examined in 13 patients of both sexes (age range 24-62 years) with mild and moderate essential hypertension (EH)." | 3.66 | Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| "The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension." | 3.66 | Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. ( Boomsma, F; Man in 't Veld, AJ; Schalekamp, MA; Wenting, GJ; Woittiez, AJ, 1982) |
| "The mechanism underlying the antihypertensive effect of acute and chronic administration of ketanserin was investigated in eight hypertensive patients." | 2.67 | The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or alpha 1-adrenergic receptors. ( Blauw, GJ; Doorenbos, CJ; van Brummelen, P; van der Velde, EA; van Zwieten, PA, 1991) |
| "Ketanserin treatment reduced the incidence of nightmares (p less than 0." | 2.67 | Serotonin antagonism reduces the adverse symptoms of beta blockade. ( Chandler, A; Gould, SE; Korlipara, K; Taylor, NA, 1990) |
| "On ketanserin treatment, the overall quality of life score was significantly improved (p = 0." | 2.67 | A placebo-controlled crossover study of ketanserin in elderly hypertensive patients. ( Gould, SE; John, SM; McCarthy, GL; McCarthy, ST, 1990) |
| " Dosage in excess of 60 mg of Kn per day caused troublesome central nervous system symptoms or headache in some patients." | 2.66 | Clinical studies with ketanserin in hypertension. ( Brown, SA; Simpson, FO; Spears, GF; Waal-Manning, HJ, 1985) |
| " The twice daily dosage schedule caused trough blood pressure control with both drugs." | 2.66 | Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. ( Alcocer, L; Copertari, P; Feruglio, F; Landi, E; Lopes, M; San Martin, C; Zin, C, 1987) |
| " The dosage of ketanserin (K) was 20 mg b." | 2.66 | Multicenter study with ketanserin in essential hypertension: an Argentine experiment. ( Bernardiner, E; Demartini, A; Genta, C; Gypen, L; Pezzano, R; Scheijgrond, H; Torres, J, 1987) |
| "Ketanserin is a novel agent that has been shown to be a specific 5-HT2-serotonergic antagonist." | 2.66 | Renal hemodynamic effects of ketanserin therapy in essential hypertension. ( Gonzalez, DG; Henderson, JD; Kaplan, NM; Lugo, CE; Ralakis, JM; Ram, CV; Zachariah, N, 1987) |
| "Ketanserin was well tolerated." | 2.66 | An evaluation of ketanserin therapy for the hypertensive diabetic patient. ( Tooke, JE; Williams, SA, 1989) |
| "Ketanserin may be a useful treatment for hypertension following coronary artery surgery as it reduced arterial pressure without reflex tachycardia." | 2.66 | Effect of ketanserin on sodium nitroprusside requirements, arterial pressure control and heart rate following coronary artery bypass surgery. ( Colvin, JR; Hodsman, NB; Kenny, GN, 1989) |
| " The rise in blood pressure between 2 and 14 h after dosing was 11/4 mm Hg supine (P less than 0." | 2.66 | Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. ( Cameron, HA; Ramsay, LE; Waller, PC, 1987) |
| " in combination with a beta-adrenergic blocking agent or a diuretic was assessed in an open study in 35 patients with essential hypertension, who had not responded to treatment with beta-blockers, diuretics or their combination." | 2.66 | Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study. ( Bartoloni, C; Dupont, P; Feltkamp, H; Johnston, CI; Kaindl, F; Steinbach, K; Zilcher, H, 1988) |
| "Ketanserin appears to be a new alternative approach in the treatment of mild and moderate essential hypertension." | 2.66 | Ketanserin versus metoprolol in the treatment of essential hypertension. ( Bernardiner, E; Lemus, J; Milei, J, 1986) |
| "Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors." | 2.66 | Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. ( Abrignani, MG; Adamo, L; Alaimo, G; Avellone, G; Cutietta, A; Giordano, U; Indovina, A; Novo, S; Pinto, A; Strano, A, 1986) |
| "Essential hypertension is a multifactorial disorder mediated by multiple mechanisms." | 2.66 | Ketanserin in essential hypertension. Effects of blood pressure on renal hemodynamics. ( Ram, CV, 1988) |
| "Treatment with ketanserin at doses proposed for clinical use (40-80 mg/day) may carry a risk of ventricular arrhythmias." | 2.66 | Prolongation of the QT interval by ketanserin. ( Cameron, HA; Ramsay, LE; Waller, PC, 1988) |
| "Ketanserin is a S2-serotonergic receptor antagonist with antihypertensive activity." | 2.66 | Ketanserin in the treatment of diabetes-associated hypertension. ( Beretta-Piccoli, C, 1988) |
| "Ketanserin is a serotonin S2 receptor antagonist with antihypertensive activity." | 2.66 | Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension. ( Bachmann, C; Beretta-Piccoli, C; Riesen, W; Salvadé, G; Zuppinger, K, 1988) |
| "Two double-blind multicenter trials were performed to compare the antihypertensive action of ketanserin, at an oral dosage of 20 mg three times daily, with that of placebo over a period of four to six weeks." | 2.66 | Double-blind comparison of ketanserin with placebo in patients with essential hypertension. ( Baeten, B; Peeters, G; Sieben, G; Symoens, J; Wellens, D, 1986) |
| "Ketanserin proved to be a safe drug to lower blood pressure." | 2.66 | Combined pharmaco-EEG and pharmacopsychological study to estimate CNS effects of ketanserin in hypertensive patients. ( Baumgartner, P; Herrmann, WM, 1986) |
| "Ketanserin was given 40 mg twice daily to 10 hypertensive patients during 4 weeks in a double-blind placebo-controlled trial." | 2.65 | Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. ( Hedner, T; Persson, B, 1984) |
| "Ketanserin is a new, specific serotonin receptor blocking agent, which causes vasodilatation, presumably by an action on the vascular wall." | 2.65 | Ketanserin in essential hypertension: effects during rest and exercise. ( Berglund, G; Hedner, T; Persson, B, 1983) |
| "The etiology of preeclampsia is still unknown." | 2.41 | Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| "(2) Urapidil is a selective alpha 1-adrenoceptor antagonist and, as such, a peripheral vasodilator." | 2.38 | Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. ( Blauw, GJ; van Brummelen, P; van Zwieten, PA, 1990) |
| "Ketanserin is a serotonin antagonist with alpha-blocking effect." | 2.38 | [Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist]. ( Knudsen, F; Nielsen, LH; Olesen, AS, 1990) |
| "Urapidil appears to be an effective antihypertensive drug with a wide spectrum of action and few side effects." | 2.37 | Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients? ( Doyle, AE, 1988) |
| "Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-hydroxytryptamine, 5HT) receptors of the 5HT2 subtype." | 2.37 | Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. ( Hedner, T; Persson, B, 1988) |
| "Ketanserin is a selective S2-serotoninergic antagonist with additional alpha 1-adrenergic blocking properties." | 2.37 | Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. ( Amery, A; Birkenhäger, W; Breckenridge, A; Bühler, F; Distler, A; Dormandy, J; Doyle, A; Frohlich, E; Hansson, L; Vanhoutte, P, 1988) |
| "Ketanserin is a specific S2 serotonergic receptor blocker with possible adrenergic blocking activities that has clinical utility in the treatment of hypertension." | 2.37 | Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin. ( Frishman, WH; Huberfeld, S; Okin, S, 1988) |
| "Stroke was significantly delayed in rats with high BRS than those with low BRS (time to 50% death was 1." | 1.34 | Arterial baroreflex: a novel target for preventing stroke in rat hypertension. ( Chen, H; Liu, AJ; Liu, JG; Ma, XJ; Shen, FM; Su, DF, 2007) |
| "Ketanserin is an anti-hypertensive drug with an ability to reduce blood pressure variability (BPV) in acute experiments in spontaneously hypertensive rats (SHRs)." | 1.32 | Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. ( Du, WM; Liu, JG; Miao, CY; Shen, FM; Su, DF; Yang, XQ, 2003) |
| " During chronic administration, however, the alpha-1 blocking effects of KET are compensated for, and the reduction in blood pressure by day 7 of KET chronic administration is maintained predominantly by persistent blockade of 5HT2 receptors." | 1.29 | Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats. ( Balasubramaniam, G; Lee, HS; Mah, SC, 1993) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Ketanserin is effective in treating hypertension following coronary artery bypass grafting with an advantage of lack of reflex tachycardia." | 1.28 | Haemodynamic effects of ketanserin following coronary artery bypass grafting. ( Boey, WK; Kumar, A; Lee, CN; Lee, EJ; Lee, TL; Woo, M, 1991) |
| "Ketanserin treatment decreased mean left ventricular mass by 9." | 1.28 | Effects of ketanserin on left ventricular hypertrophy in hypertensive patients. ( Alcocer, L; Chávez, A; Cobo, C, 1990) |
| "Ketanserin is a serotonin antagonist with age-related antihypertensive efficacy." | 1.28 | Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives. ( Karpanou, EA; Kourtis, TK; Paleologos, AA; Pitsavos, CE; Toutouzas, PK; Vyssoulis, GP, 1990) |
| "Ketanserin was effective in lowering blood pressure in all patients, 6 of whom became normotensive." | 1.28 | Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients. ( Bedogna, V; Casagrande, P; Graziani, MS; Loschiavo, C; Maschio, G; Nicoli, M; Valvo, E, 1990) |
| "Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94." | 1.28 | Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. ( Konishi, M; Sakakura, M; Tsushima, N, 1990) |
| "Ketanserin is a serotonin S2-receptor antagonist that is an effective antihypertensive agent with a greater blood pressure reduction in older patients." | 1.28 | Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics? ( Gould, SE; Hosie, J; Silas, JH, 1990) |
| "Ketanserin was found to be a competitive antagonist of the noradrenaline-induced constrictions (pA2 = 7." | 1.27 | Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation. ( McLennan, PL; Taylor, DA, 1984) |
| "Prazosin pretreatment and TAB prevented these effects." | 1.27 | Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin. ( Angus, JA; Wright, CE, 1983) |
| "In the spontaneously hypertensive rat (SHR), ketanserin and the ketanserin analogues R56413 and ritanserin were studied with regard to their ability to reduce the blood pressure in conscious rats and shift the dose-response curves for phenylephrine and serotonin (5-HT) in pithed rats after acute administration." | 1.27 | Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action. ( Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1985) |
| "Ketanserin is a serotonin antagonist with high affinity for S2-serotonergic receptors, which mediate the vasoconstrictor effects of serotonin." | 1.27 | Ketanserin: a possible tool for studying the role of serotonin in hypertension. ( Boomsma, F; Man in't Veld, AJ; Schalekamp, MA; Wenting, GJ; Woittiez, AJ, 1985) |
| "Ketanserin is a 5-HT2 antagonist with alpha-adrenoreceptor blocking activity." | 1.27 | Ketanserin in the acute management of severe hypertension. ( Kincaid-Smith, P; Murphy, BF; Whitworth, JA, 1985) |
| "Ketanserin was given intravenously to 10 patients with hypertensive crisis or resistant hypertension and orally to 15 patients with mild to severe hypertension for 1 year." | 1.27 | Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin. ( Brimichová, G; Dzúrik, R; Fetkovská, N; Tison, P, 1985) |
| "Twenty-seven patients with untreated hypertension and/or intermittent claudication received a bolus intravenous (i." | 1.27 | Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. ( Freitag, B; Pointel, JP; Schmitt, C; Stoltz, JF; Voisin, P; Zannad, F, 1985) |
| " Dose-response curves to serotonin in arteries from hypertensive rats were shifted significantly to the left compared with those in arteries from normotensive rats (ED25: DOCA-treated = 2." | 1.27 | Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension. ( Thompson, LP; Webb, RC, 1987) |
| "Ketanserin is an antihypertensive compound that binds to 5-HT2 receptors as well as to alpha 1-adrenoceptors." | 1.27 | Effects of ketanserin on hemodynamics and baroreflex effects in conscious spontaneously hypertensive rats. ( Smits, JF; Struyker-Boudier, HA; Tijssen, CM; van Essen, H, 1987) |
| " Whereas the blood pressure reduction to acute administration of ketanserin was directly related to its ability to shift the dose-response curve of phenylephrine (alpha 1-adrenergic blockade), the same relationship was not apparent following chronic treatment with ketanserin." | 1.27 | Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat. ( Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1988) |
| "Ketanserin was given alone, 40 mg o." | 1.27 | Treatment of arterial hypertension with ketanserin in mono- and combination therapy. ( Berglund, G; Hedner, T; Persson, B; Pettersson, A, 1985) |
| "Ketanserin is a pure antagonist of serotonin S2-receptors, in blood vessels, platelets and bronchial tissue." | 1.27 | Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism. ( Assogna, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Lais, A; Pisculli, M; Romeo, M; Valgiusti, FC, 1986) |
| " In the intact animal it may cause increases or decreases of blood pressure and in isolated blood vessels contraction or relaxation depending on the species and vascular bed studied, the route of administration and the dosage used." | 1.27 | Serotonin and the blood vessel wall. ( Lüscher, TF; Vanhoutte, PM, 1986) |
| "Ketanserin was administered intravenously as either 20 or 10 mg boluses to 16 patients with severe preeclampsia in labor." | 1.27 | Intrapartum treatment of preeclamptic hypertension by ketanserin. ( Hulme, VA; Odendaal, HJ, 1986) |
| "Ketanserin is a new antihypertensive agent with affinity to serotonin (5-HT)2 receptors and at higher concentrations also to alpha 1-adrenoceptors." | 1.27 | Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat. ( Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1985) |
| "Ketanserin has a high affinity for the S2-receptors, and thus it will antagonise the stimulating effect of serotonin at these receptors." | 1.27 | The relevance of serotonin antagonism in the treatment of hypertension. ( Doyle, AE, 1988) |
| "Ketanserin treatment administered over a period of 8 weeks, decreased arterial pressure in patients with essential hypertension and, to a lesser extent, in diabetics, but not in normal subjects." | 1.27 | Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension. ( Beretta-Piccoli, C; Waser, M; Ziegler, WH, 1988) |
| " Pharmacokinetic variables after a single dose were similar to those reported in healthy volunteers, with median values for Cmax 112 ng." | 1.27 | The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects. ( Ramsay, LE; Tucker, GT; Waller, PC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 215 (68.47) | 18.7374 |
| 1990's | 78 (24.84) | 18.2507 |
| 2000's | 17 (5.41) | 29.6817 |
| 2010's | 1 (0.32) | 24.3611 |
| 2020's | 3 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, B | 1 |
| Chaddha, M | 1 |
| Elasbali, AM | 1 |
| Zhu, Z | 1 |
| Jairajpuri, DS | 1 |
| Alhumaydhi, FA | 1 |
| Mohammad, T | 1 |
| Abdulmonem, WA | 1 |
| Sharaf, SE | 1 |
| Hassan, MI | 1 |
| Bhat, AD | 1 |
| Keasler, PM | 1 |
| Kolluru, L | 1 |
| Dombrowski, MM | 1 |
| Palanisamy, A | 1 |
| Singh, PM | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Bijvank, SW | 1 |
| Visser, W | 2 |
| Duvekot, JJ | 1 |
| Steegers, EA | 2 |
| Edens, MA | 1 |
| Roofthooft, DW | 1 |
| Vulto, AG | 2 |
| Hanff, LM | 2 |
| Su, DF | 8 |
| Miao, CY | 4 |
| Russell, A | 1 |
| Banes, A | 1 |
| Berlin, H | 1 |
| Fink, GD | 1 |
| Watts, SW | 4 |
| Ogawa, T | 1 |
| Sugidachi, A | 1 |
| Tanaka, N | 1 |
| Fujimoto, K | 1 |
| Asai, F | 1 |
| Du, WM | 1 |
| Liu, JG | 2 |
| Shen, FM | 3 |
| Yang, XQ | 1 |
| Xie, HH | 1 |
| Yu, H | 1 |
| Chu, ZX | 1 |
| Yuan, WJ | 1 |
| Banga, FR | 1 |
| Bolte, AC | 3 |
| Dekker, GA | 3 |
| van Geijn, HP | 4 |
| Chang, CP | 1 |
| Chen, SH | 1 |
| Lin, MT | 1 |
| Liu, AJ | 1 |
| Ma, XJ | 1 |
| Chen, H | 1 |
| Wang, J | 1 |
| Ni, CR | 1 |
| Yu, JG | 1 |
| Wang, WZ | 1 |
| Petkovská, N | 1 |
| Brimichová, G | 3 |
| Tison, P | 3 |
| Dzúrik, R | 3 |
| Van Nueten, JM | 2 |
| Janssen, PA | 1 |
| Van Beek, J | 1 |
| Xhonneux, R | 1 |
| Verbeuren, TJ | 1 |
| Vanhoutte, PM | 3 |
| Vermylen, J | 1 |
| Fiocchi, R | 4 |
| Fagard, R | 6 |
| Lijnen, P | 6 |
| Staessen, J | 6 |
| Amery, A | 7 |
| Wing, LM | 2 |
| Chalmers, JP | 2 |
| West, MJ | 2 |
| Bune, AJ | 2 |
| Ayres, B | 2 |
| Graham, JR | 2 |
| Van Zwieten, PA | 8 |
| Timmermans, PB | 1 |
| Van Brummelen, P | 6 |
| Hedner, T | 20 |
| Persson, B | 19 |
| Andrén, L | 1 |
| Svensson, A | 1 |
| Dahlöf, B | 1 |
| Eggertsen, R | 1 |
| Hansson, L | 3 |
| Moerman, E | 1 |
| de Schaepdryver, A | 1 |
| Fetkovská, N | 6 |
| Berglund, G | 6 |
| Weiner, CP | 2 |
| Socol, ML | 2 |
| Vaisrub, N | 1 |
| Anthony, M | 1 |
| Ernst, E | 1 |
| Matrai, A | 1 |
| Pettersson, A | 9 |
| Henning, M | 1 |
| McLennan, PL | 1 |
| Taylor, DA | 1 |
| Su, C | 1 |
| Uruno, T | 1 |
| van der Starre, PJ | 4 |
| Scheijgrond, HW | 2 |
| Reneman, RS | 3 |
| Kolling, JB | 1 |
| Diedericks, BJ | 1 |
| Roelofse, JA | 1 |
| De Wet, JI | 1 |
| Fischler, M | 1 |
| Dentan, M | 1 |
| Westerman, MN | 1 |
| Vourc'h, G | 1 |
| Freitag, B | 2 |
| Wright, CE | 1 |
| Angus, JA | 1 |
| Omvik, P | 2 |
| Lund-Johansen, P | 2 |
| Zabludowski, JR | 1 |
| Zoccali, C | 1 |
| Isles, CG | 1 |
| Murray, GD | 2 |
| Robertson, JI | 3 |
| Inglis, GC | 1 |
| Fraser, R | 1 |
| Ball, SG | 2 |
| Gelfan, R | 1 |
| Wenting, GJ | 6 |
| Man in 't Veld, AJ | 2 |
| Woittiez, AJ | 4 |
| Boomsma, F | 2 |
| Schalekamp, MA | 6 |
| Kacprowicz, AT | 1 |
| Shaw, PG | 1 |
| Moulds, RF | 1 |
| Bury, RW | 1 |
| van den Broeke, JJ | 1 |
| Karliczek, GF | 1 |
| Brenken, U | 1 |
| Schokkenbroek, R | 1 |
| Homan van der Heide, JN | 1 |
| De Cree, J | 4 |
| Leempoels, J | 3 |
| De Cock, W | 2 |
| Geukens, H | 2 |
| Verhaegen, H | 3 |
| De Clerck, F | 1 |
| Jageneau, A | 1 |
| Dom, J | 1 |
| Gilbert, L | 1 |
| Webb, RC | 2 |
| Felding, M | 1 |
| Cold, GE | 1 |
| Jacobsen, CJ | 1 |
| Stjernholm, P | 1 |
| Voss, K | 1 |
| Modica, G | 1 |
| Monte, I | 1 |
| Guerini Rocco, C | 1 |
| Frishman, WH | 4 |
| Huberfeld, S | 2 |
| Okin, S | 3 |
| Wang, YH | 1 |
| Kumar, A | 2 |
| Shareef, B | 1 |
| Azzadin, A | 1 |
| Mysliwiec, J | 1 |
| Wollny, T | 1 |
| Mysliwiec, M | 1 |
| Buczko, W | 2 |
| Petry, A | 1 |
| Wulf, H | 1 |
| Baumgärtel, M | 1 |
| Vandenbroucke, G | 2 |
| Foubert, L | 2 |
| Coddens, J | 1 |
| DeLoof, T | 1 |
| Evenepoel, MC | 2 |
| Balasubramaniam, G | 1 |
| Lee, HS | 1 |
| Mah, SC | 1 |
| Poletti, L | 1 |
| Fogari, R | 3 |
| Bressan, MA | 1 |
| Poggio, M | 1 |
| Daglio, M | 1 |
| Ripamonti, L | 1 |
| Vlacos, D | 1 |
| Azzaretti, G | 1 |
| Knypl, K | 1 |
| Wocial, B | 1 |
| Berent, H | 1 |
| Kuçzyńska, K | 1 |
| Wasowska, T | 1 |
| Brym, E | 1 |
| Czerniewska, E | 1 |
| Wacławek-Maczkowska, J | 1 |
| Januszewicz, W | 1 |
| Kay, R | 1 |
| Poon, WS | 1 |
| Nicholls, MG | 1 |
| Gleerup, G | 1 |
| Winther, K | 1 |
| Zoppi, A | 2 |
| Derosa, G | 1 |
| Lusardi, P | 1 |
| Mugellini, A | 1 |
| Lazzari, P | 2 |
| van der Stroom, JG | 1 |
| van Wezel, HB | 1 |
| Langemeijer, JJ | 1 |
| Korsten, HH | 1 |
| Kooyman, J | 1 |
| Kal, JE | 1 |
| Porsius, M | 1 |
| van den Ende, R | 1 |
| Steyn, DW | 4 |
| Odendaal, HJ | 5 |
| Lee, JY | 1 |
| Hancock, AA | 1 |
| Warner, RB | 1 |
| Brune, ME | 1 |
| Meyer, MD | 1 |
| DeBernardis, JF | 1 |
| van Eyck, J | 1 |
| Strack van Schijndel, RJ | 1 |
| Grewall, P | 1 |
| Banes, AK | 1 |
| van Schie, DL | 1 |
| de Jeu, RM | 1 |
| Alberio, L | 1 |
| Beretta-Piccoli, C | 7 |
| Tanzi, F | 1 |
| Koch, P | 1 |
| Zehender, M | 3 |
| Belousov, IuB | 1 |
| Krivonkin, KIu | 1 |
| Kong, XB | 2 |
| Cheng, Y | 2 |
| Blauw, GJ | 5 |
| Vyssoulis, GP | 2 |
| Karpanou, EA | 2 |
| Pitsavos, CE | 2 |
| Kourtis, TK | 2 |
| Paleologos, AA | 2 |
| Toutouzas, PK | 2 |
| Van Gelderen, EM | 1 |
| Saxena, PR | 2 |
| Lüscher, TF | 2 |
| Tanner, FC | 1 |
| Bühler, FR | 10 |
| Deguchi, F | 2 |
| Saito, T | 2 |
| Inagaki, Y | 2 |
| Bogle, RG | 1 |
| Mikulic, E | 1 |
| Rull, D | 1 |
| Puntoni, L | 1 |
| Metelitsa, VI | 1 |
| Filatova, NP | 1 |
| Doyle, AE | 4 |
| Amstein, R | 8 |
| Janssens, M | 2 |
| Symoens, J | 5 |
| Robertson, MP | 1 |
| Lee, EJ | 1 |
| Lee, TL | 1 |
| Woo, M | 1 |
| Boey, WK | 1 |
| Lee, CN | 1 |
| Filippenko, NG | 1 |
| Dement'eva, NG | 1 |
| Povetkov, SV | 1 |
| Mertens, MJ | 1 |
| Pfaffendorf, M | 1 |
| Mollo, P | 1 |
| Doorenbos, CJ | 2 |
| van der Velde, EA | 1 |
| Aliberti, G | 1 |
| D'Erasmo, E | 1 |
| Oddo, CM | 1 |
| Vecci, E | 1 |
| Soro, S | 7 |
| Grassi, A | 1 |
| Pasanisi, F | 3 |
| Ferrara, LA | 7 |
| Liu, GS | 1 |
| Huang, DX | 1 |
| Yang, XS | 1 |
| Wang, SR | 1 |
| Tang, XL | 1 |
| Xing, JL | 1 |
| Peng, SY | 1 |
| Tong, YZ | 1 |
| Letizia, C | 1 |
| Sellini, M | 1 |
| Scavo, D | 1 |
| Carleo, R | 1 |
| Gobbo, M | 1 |
| Bonavita, M | 1 |
| De Matteo, A | 1 |
| Gallo, M | 1 |
| Gatti, A | 1 |
| Korlipara, K | 2 |
| Gould, SE | 8 |
| Taylor, NA | 3 |
| Chandler, A | 1 |
| Bruning, TA | 1 |
| Distler, A | 2 |
| Gambini, G | 2 |
| Rossi, S | 1 |
| Valori, C | 2 |
| Brogden, RN | 1 |
| Sorkin, EM | 1 |
| Arfiero, S | 1 |
| Ometto, R | 1 |
| Vincenzi, M | 1 |
| Shu, CC | 1 |
| Chan, KH | 1 |
| Lee, TY | 1 |
| Lui, PW | 1 |
| Daiy, YP | 1 |
| Ma, JY | 1 |
| Chow, LH | 1 |
| Meinertz, T | 2 |
| Hohnloser, S | 2 |
| Geibel, A | 2 |
| Hartung, J | 2 |
| Seiler, KU | 3 |
| Just, H | 2 |
| Terrachini, V | 1 |
| Provinciali, L | 1 |
| Barbara, C | 1 |
| Masperone, MA | 1 |
| Zanna, C | 3 |
| Romeo, M | 4 |
| Bruzzone, F | 1 |
| Canale, C | 1 |
| Bielmann, P | 1 |
| Leduc, G | 1 |
| Gutkowska, J | 1 |
| Davignon, J | 1 |
| Cobo, C | 1 |
| Alcocer, L | 2 |
| Chávez, A | 1 |
| Coto, V | 2 |
| Cocozza, M | 2 |
| Oliviero, U | 2 |
| Lucariello, A | 2 |
| Picano, T | 2 |
| Castaldo, B | 1 |
| Iovino, V | 1 |
| Cacciatore, L | 2 |
| Nielsen, LH | 1 |
| Knudsen, F | 1 |
| Olesen, AS | 1 |
| Elliott, HL | 5 |
| Meredith, PA | 4 |
| Taylor, FR | 1 |
| Sebeková, K | 1 |
| Raucinová, M | 1 |
| Jurecková, K | 1 |
| Loschiavo, C | 2 |
| Valvo, E | 2 |
| Bedogna, V | 2 |
| Casagrande, P | 2 |
| Graziani, MS | 2 |
| Nicoli, M | 1 |
| Maschio, G | 2 |
| McCormack, PM | 1 |
| Cox, JP | 1 |
| Marron, J | 1 |
| Mee, F | 1 |
| Atkins, N | 1 |
| O'Brien, E | 1 |
| O'Malley, K | 1 |
| Konishi, M | 1 |
| Sakakura, M | 1 |
| Tsushima, N | 1 |
| van Oene, JC | 2 |
| Lavezzaro, G | 1 |
| Ladetto, PE | 1 |
| Valente, M | 1 |
| Stramignoni, D | 1 |
| Assogna, G | 7 |
| Salvetti, A | 1 |
| McCarthy, ST | 1 |
| McCarthy, GL | 1 |
| John, SM | 1 |
| Malatino, LS | 1 |
| Stancanelli, B | 1 |
| Greco, G | 1 |
| Polizzi, G | 1 |
| Tamburino, G | 1 |
| Rosa, C | 1 |
| Ghione, S | 1 |
| Silas, JH | 2 |
| Hosie, J | 2 |
| Giorgetti, P | 1 |
| Kristensen, KS | 1 |
| Jensen, HA | 1 |
| Svendsen, TL | 1 |
| Möllhoff, T | 2 |
| Van Aken, H | 3 |
| Mulier, JP | 2 |
| Müller, E | 2 |
| Lauwers, P | 2 |
| Pasotti, C | 1 |
| Nicrosini, S | 1 |
| Corradi, L | 1 |
| Gradin, K | 4 |
| Baudouin-Legros, M | 1 |
| Le Quan-Bui, KH | 1 |
| Guicheney, P | 1 |
| Kamal, LA | 1 |
| Meyer, P | 2 |
| Nelson, MA | 1 |
| Coghlan, JP | 2 |
| Denton, DA | 2 |
| Mills, EH | 1 |
| Scoggins, BA | 2 |
| Spence, CD | 1 |
| Whitworth, JA | 3 |
| Hoing, M | 1 |
| De Ryck, M | 1 |
| Man in't Veld, AJ | 4 |
| Rorive, G | 5 |
| Waal-Manning, HJ | 1 |
| Brown, SA | 1 |
| Spears, GF | 1 |
| Simpson, FO | 1 |
| Fasano, ML | 6 |
| Rubba, P | 2 |
| Marotta, G | 1 |
| Mancini, M | 3 |
| Murphy, BF | 1 |
| Kincaid-Smith, P | 1 |
| Mantero, F | 1 |
| Rocco, S | 2 |
| Opocher, G | 1 |
| Armanini, D | 1 |
| Boscaro, M | 1 |
| D'Agostino, D | 1 |
| Zannad, F | 1 |
| Voisin, P | 1 |
| Pointel, JP | 1 |
| Schmitt, C | 1 |
| Stoltz, JF | 1 |
| Demoen, B | 1 |
| Thompson, LP | 1 |
| Jennings, AA | 1 |
| Opie, LH | 1 |
| Smits, JF | 2 |
| van Essen, H | 1 |
| Tijssen, CM | 1 |
| Struyker-Boudier, HA | 2 |
| Frohlich, ED | 1 |
| Novo, S | 3 |
| Alaimo, G | 3 |
| Giordano, U | 2 |
| Raineri, A | 2 |
| Strano, A | 3 |
| Hannedouche, T | 1 |
| Fillastre, JP | 1 |
| Mimran, A | 1 |
| de Tréglodé, D | 1 |
| Schardt, F | 1 |
| Rosenthal, T | 1 |
| Grossman, E | 1 |
| Zin, C | 1 |
| Copertari, P | 1 |
| Landi, E | 1 |
| San Martin, C | 1 |
| Lopes, M | 1 |
| Feruglio, F | 1 |
| Bertel, O | 3 |
| Brunner, HR | 3 |
| Follath, F | 3 |
| Solèr, M | 1 |
| Vallotton, M | 1 |
| Bolt, GR | 1 |
| Dhasmana, KM | 1 |
| Leary, WP | 1 |
| Reyes, AJ | 1 |
| van der Byl, K | 1 |
| Maharaj, B | 1 |
| Demartini, A | 1 |
| Pezzano, R | 1 |
| Bernardiner, E | 4 |
| Torres, J | 1 |
| Genta, C | 1 |
| Scheijgrond, H | 1 |
| Gypen, L | 1 |
| Brouwer, RM | 2 |
| Ram, CV | 2 |
| Gonzalez, DG | 1 |
| Kaplan, NM | 1 |
| Ralakis, JM | 1 |
| Henderson, JD | 1 |
| Lugo, CE | 1 |
| Zachariah, N | 1 |
| Stott, DJ | 1 |
| Milei, J | 5 |
| Lemus, J | 4 |
| Schiavone, M | 1 |
| Lucioni, MC | 1 |
| Blaton, V | 1 |
| Hollez, P | 1 |
| Donnelly, R | 4 |
| Reid, JL | 4 |
| Levinson, PD | 2 |
| Zimlichman, R | 2 |
| Goldstein, DS | 2 |
| Keiser, HR | 2 |
| Ferracin, F | 1 |
| Pletscher, A | 2 |
| Gradoli, C | 1 |
| Proietti, MG | 1 |
| Pinchi, G | 1 |
| Fioroni, E | 1 |
| Neri, G | 1 |
| Iovine, C | 1 |
| Chau, NP | 1 |
| Pithois-Merli, I | 1 |
| Levenson, J | 1 |
| Simon, AC | 1 |
| Docherty, JR | 1 |
| Licata, G | 1 |
| Scaglione, R | 1 |
| Parrinello, G | 1 |
| Capuana, G | 1 |
| Mazzola, G | 1 |
| Lipari, R | 1 |
| Galantino, L | 1 |
| Castello, R | 1 |
| de Leeuw, PW | 2 |
| Finkielman, S | 3 |
| Nahmod, VE | 1 |
| Coto, F | 1 |
| Regenthal, R | 1 |
| Voigt, H | 1 |
| Metelitsa, TV | 1 |
| Tooke, JE | 1 |
| Williams, SA | 1 |
| Antonicelli, R | 1 |
| Andreoni, A | 1 |
| Saccomanno, G | 1 |
| Gambini, C | 1 |
| Paciaroni, E | 1 |
| Di Veroli, C | 1 |
| Pastorelli, R | 1 |
| Reutter, F | 2 |
| Vallotton, MB | 2 |
| Tsuda, K | 2 |
| Nishio, I | 2 |
| Masuyama, Y | 3 |
| Uehara, Y | 1 |
| Numabe, A | 1 |
| Hirawa, N | 1 |
| Ishimitsu, T | 1 |
| Takada, S | 1 |
| Matsuoka, H | 1 |
| Yagi, S | 1 |
| Sugimoto, T | 1 |
| Reijnders, PJ | 1 |
| Hughes, EW | 1 |
| Hodkinson, BP | 1 |
| Hodsman, NB | 1 |
| Colvin, JR | 1 |
| Kenny, GN | 1 |
| Heer, K | 1 |
| Uhl, D | 1 |
| vd Meiracker, AJ | 1 |
| Di Lorenzo, M | 1 |
| Feo, B | 1 |
| Pompa, D | 1 |
| Breckenridge, A | 3 |
| van den Meiracker, AH | 2 |
| Rosenthal, J | 1 |
| Koehle, W | 1 |
| Gruebel, B | 1 |
| Fisher, R | 2 |
| Waller, PC | 5 |
| Solomon, SA | 1 |
| Ramsay, LE | 6 |
| Cameron, HA | 4 |
| Birkenhäger, WH | 1 |
| Bartoloni, C | 1 |
| Dupont, P | 1 |
| Feltkamp, H | 2 |
| Johnston, CI | 1 |
| Steinbach, K | 1 |
| Zilcher, H | 1 |
| Kaindl, F | 1 |
| Huberfeld, SI | 1 |
| Soberman, J | 1 |
| Laifer, L | 1 |
| Greenberg, S | 1 |
| Lapsker, J | 1 |
| Charlap, S | 1 |
| Strom, JA | 1 |
| van der Pol, JM | 1 |
| Oei, TT | 1 |
| Seedat, YK | 1 |
| Parag, KB | 1 |
| De Lorenzo, A | 3 |
| Ceccanti, M | 3 |
| Cavalieri, G | 1 |
| Attilia, ML | 2 |
| Ritsema van Eck, HJ | 1 |
| Zantvoort, FA | 1 |
| Pisculli, M | 1 |
| Di Giovanni, MG | 1 |
| Lais, A | 1 |
| Valgiusti, FC | 1 |
| Harinck-de Weerd, JE | 1 |
| Abrignani, MG | 2 |
| Cutietta, A | 2 |
| Zanchetti, A | 1 |
| Gordin, A | 1 |
| Saraste, K | 1 |
| Turanlahti, M | 1 |
| Sundberg, S | 1 |
| Kane, JA | 1 |
| Tooley, M | 1 |
| Sibbald, B | 1 |
| Mauersberger, H | 1 |
| Palermo, A | 1 |
| Mara, G | 1 |
| Pizza, N | 1 |
| Costantini, C | 1 |
| del Rosso, G | 1 |
| Libretti, A | 1 |
| Dona, G | 1 |
| Ribeiro, A | 1 |
| Tammaro, AE | 1 |
| Navis, G | 1 |
| de Jong, PE | 1 |
| van der Hem, GK | 1 |
| de Zeeuw, D | 1 |
| Petterson, A | 1 |
| Andersson, O | 1 |
| Cruz, J | 1 |
| Moscovici, H | 1 |
| Silva, AN | 1 |
| Geyer, G | 1 |
| Stumpe, KO | 1 |
| Berges, LC | 1 |
| Stokes, GS | 1 |
| Mennie, BA | 1 |
| Marwood, JF | 1 |
| Cashman, JN | 1 |
| Thompson, MA | 1 |
| Bennett, A | 1 |
| Houghton, K | 1 |
| Carter, JA | 2 |
| Hulme, VA | 1 |
| Avellone, G | 1 |
| Pinto, A | 1 |
| Adamo, L | 1 |
| Indovina, A | 1 |
| Zachariah, PK | 2 |
| Burnett, JC | 1 |
| Ritter, SG | 1 |
| Strong, CG | 1 |
| Casiglia, E | 1 |
| Gava, R | 1 |
| Nicolin, P | 1 |
| Semplicini, A | 1 |
| Rossi, GP | 1 |
| Buzzaccarini, F | 1 |
| Pessina, AC | 1 |
| Dal Palù, C | 1 |
| Cavaleri, G | 1 |
| Chandler, TC | 1 |
| Murphy, JJ | 1 |
| Whincup, PH | 1 |
| Wilcox, RG | 1 |
| Safar, M | 1 |
| Ito, K | 1 |
| Omae, T | 1 |
| Ikeda, M | 1 |
| Iimura, O | 1 |
| Yoshinaga, K | 1 |
| Ishii, M | 1 |
| Kaneko, Y | 1 |
| Mizuno, Y | 1 |
| Takeda, T | 1 |
| Nakamura, H | 1 |
| Hirata, F | 1 |
| Yasugi, T | 1 |
| Mizuno, M | 1 |
| Saito, E | 1 |
| Ishikawa, T | 1 |
| Tada, N | 1 |
| Nakaya, N | 1 |
| Homma, Y | 1 |
| Takeuchi, I | 1 |
| Kosoglou, T | 1 |
| Cressman, MD | 1 |
| Vlasses, PH | 1 |
| Rocci, ML | 1 |
| Gabos, C | 1 |
| Ferguson, RK | 1 |
| Salvadé, G | 1 |
| Bachmann, C | 1 |
| Riesen, W | 1 |
| Zuppinger, K | 1 |
| Nelson, M | 1 |
| Tresham, JJ | 1 |
| Smits, J | 1 |
| van Dorsten, F | 1 |
| Struyker Boudier, H | 1 |
| Iannuzzi, A | 1 |
| McGourty, JC | 1 |
| Cowen, KJ | 1 |
| Findlay, JG | 1 |
| Hughes, DM | 1 |
| Noda, H | 2 |
| Isaka, M | 2 |
| Ito, Y | 2 |
| Fujita, T | 2 |
| Sánchez, RA | 1 |
| Otero, F | 1 |
| Ramírez, AJ | 1 |
| Degrossi, O | 1 |
| Glenny, J | 1 |
| Marcó, EJ | 1 |
| Sato, Y | 1 |
| Arakawa, K | 1 |
| Sasaki, J | 1 |
| Saku, K | 1 |
| Ideishi, S | 1 |
| Saeki, Y | 1 |
| Baba, K | 1 |
| Ikeda, K | 1 |
| Kato, Y | 1 |
| Ohba, H | 1 |
| Doi, H | 1 |
| Janka, HU | 1 |
| Mehnert, H | 1 |
| Bayman, IW | 1 |
| Turner, JF | 1 |
| Minami, M | 2 |
| Hamaue, N | 2 |
| Togashi, H | 2 |
| Matsumoto, M | 2 |
| Yoshioka, M | 2 |
| Saito, H | 2 |
| Anger, C | 2 |
| Prys-Roberts, C | 1 |
| Vanhoutte, P | 1 |
| Birkenhäger, W | 1 |
| Bühler, F | 1 |
| Dormandy, J | 1 |
| Doyle, A | 1 |
| Frohlich, E | 1 |
| De Luca, N | 1 |
| Rosiello, G | 1 |
| Crispino, M | 1 |
| Volpe, M | 1 |
| Galletti, P | 1 |
| Buzzetti, G | 1 |
| Trimarco, B | 1 |
| Wiecek, A | 1 |
| Grzeszczak, W | 1 |
| Weiss, YA | 1 |
| Fournier, V | 1 |
| Pannier, B | 1 |
| Laurent, S | 1 |
| Safar, ME | 1 |
| Murray, WB | 1 |
| Daniel, CH | 1 |
| Wellens, D | 2 |
| Carlier, PG | 1 |
| Krzesinski, JM | 1 |
| Amemiya, N | 1 |
| Waser, M | 1 |
| Ziegler, WH | 1 |
| Brewer, HB | 1 |
| Egan, B | 1 |
| Conlon, ME | 1 |
| Campbell, R | 1 |
| Schork, N | 1 |
| Zwiefler, A | 1 |
| Julius, S | 1 |
| Tsuda, S | 1 |
| Yokoyama, K | 1 |
| Inada, Y | 1 |
| Shimizu, R | 1 |
| Fujita, M | 1 |
| Kaya, K | 1 |
| Farinaro, E | 1 |
| Celentano, E | 1 |
| Tucker, GT | 1 |
| Peeters, G | 1 |
| Baeten, B | 1 |
| Sieben, G | 1 |
| Sheps, SG | 1 |
| Schirger, A | 1 |
| Fisher, LD | 1 |
| Spiekerman, RE | 1 |
| Araas, FJ | 1 |
| Collins, JB | 1 |
| Agerter, DC | 1 |
| Herrmann, WM | 1 |
| Baumgartner, P | 1 |
| Hoch, D | 1 |
| Lawin, P | 1 |
| Lichtenthal, PR | 1 |
| Wade, LD | 1 |
| Rossi, EC | 1 |
| Zazgornik, J | 1 |
| Scholz, N | 1 |
| Kuska, J | 1 |
| Minar, E | 1 |
40 reviews available for ketanserin and Hypertension
| Article | Year |
|---|---|
Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hydralazine; Hypertension; Infant | 2023 |
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
Arterial baroreflex function in conscious rats.
Topics: Animals; Aorta; Baroreflex; Blood Pressure; Denervation; Hypertension; Ketanserin; Rats; Rats, Inbre | 2002 |
Role of alpha adrenoceptors in hypertension and in antihypertensive drug treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Azepines; | 1984 |
Serotonin antagonists.
Topics: Cyproheptadine; Depression; Ergotamine; Humans; Hypertension; Ketanserin; Lisuride; Methysergide; Mi | 1984 |
Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Coronary Disease; | 1995 |
Serotonin and the heart.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Cardiovascular Diseases; Endothe | 2000 |
Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin.
Topics: Adult; Antihypertensive Agents; Clinical Trials as Topic; Female; Humans; Hypertension; Ketanserin; | 2000 |
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diureti | 2001 |
Serotonergic receptors and drugs in hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Anim | 1992 |
[Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
Topics: Aged; Animals; Arterial Occlusive Diseases; Blood Platelets; Cardiovascular Diseases; Cerebrovascula | 1992 |
[Serotonergic antagonist].
Topics: Animals; Antihypertensive Agents; Humans; Hypertension; Ketanserin; Serotonin Antagonists | 1992 |
Age-related effects of 5-HT2 antagonists.
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Humans; Hypertension; Ketanserin; Middle Aged | 1991 |
Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
Topics: Humans; Hypertension; Ketanserin; Receptors, Serotonin; Serotonin | 1991 |
Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetic Angiopathies; Foot Ulcer; Humans; Hypertensi | 1991 |
Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Humans; Hypertension | 1990 |
Clinical aspects during therapy with the serotonin antagonist ketanserin.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Combinat | 1990 |
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
Topics: Animals; Humans; Hypertension; Ketanserin; Vascular Diseases | 1990 |
Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Ketanserin; Piperaz | 1990 |
[Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist].
Topics: Anesthesia, Intravenous; Humans; Hypertension; Ketanserin; Postoperative Complications; Receptors, S | 1990 |
Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
Topics: Animals; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Ketanserin; Methoxamine; Phe | 1985 |
Serotonin agonists and antagonists in experimental hypertension.
Topics: Animals; Blood Pressure; Central Nervous System; Hypertension; Ketanserin; Receptors, Serotonin; Ser | 1987 |
The rationale for ketanserin therapy in hypertension.
Topics: Animals; Arteriosclerosis; Blood Platelets; Blood Pressure; Hemodynamics; Hormones; Humans; Hyperten | 1987 |
Why are the antihypertensive effects of ketanserin age-related?
Topics: Adult; Aged; Aging; Humans; Hypertension; Ketanserin; Middle Aged | 1988 |
[The clinical significance of serotonin antagonists].
Topics: Arteriosclerosis Obliterans; Humans; Hypertension; Ischemia; Ketanserin; Leg; Serotonin Antagonists | 1989 |
[Serotonin and its physiological and pathophysiological roles. Ketanserin].
Topics: Blood Pressure; Humans; Hypertension; Ketanserin; Receptors, Serotonin; Serotonin | 1989 |
Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Humans; Hypertension; Ketanserin; Middle Aged; Platelet | 1989 |
Treatment of the elderly hypertensive: a clinical perspective.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Calcium Channel Blockers; Cerebrovascular Diso | 1988 |
Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Humans; Hypertension; Ketanserin; Labetalol; | 1988 |
Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Cardiovascular System; Dose-Response Rela | 1988 |
Ageing, serotonin and ketanserin.
Topics: Adult; Aged; Aged, 80 and over; Aging; Humans; Hypertension; Ketanserin; Middle Aged; Serotonin | 1988 |
[Role of serotonin in the regulation of the circulatory system].
Topics: Animals; Humans; Hypertension; Ketanserin; Muscle, Smooth, Vascular; Piperidines; Rats; Receptors, S | 1985 |
Antihypertensive mechanism of ketanserin in postoperative hypertension after cardiopulmonary bypass.
Topics: Aged; Blood Pressure; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Epinephrine; Humans; | 1988 |
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.
Topics: Humans; Hypertension; Ketanserin; Muscle Contraction; Muscle, Smooth, Vascular; Platelet Aggregation | 1988 |
Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin.
Topics: Animals; Blood Viscosity; Hemodynamics; Humans; Hypertension; Ketanserin; Platelet Aggregation Inhib | 1988 |
[Cardiovascular pharmacology of serotonin and its antagonists].
Topics: Animals; Drug Synergism; Humans; Hypertension; Ketanserin; Serotonin; Vasoconstriction; Vasoconstric | 1988 |
[Clinical profile of a new antihypertensive agents. Ketanserin].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Hemodynamics | 1988 |
[Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
Topics: Antihypertensive Agents; Arterial Occlusive Diseases; Blood Pressure; Humans; Hypertension; Ketanser | 1987 |
Hemodynamic effects of ketanserin in experimental hypertension.
Topics: Animals; Blood Pressure; Hemodynamics; Hypertension; Ketanserin; Rats; Rats, Inbred SHR; Rats, Inbre | 1987 |
Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man.
Topics: Blood Pressure; Hemodynamics; Humans; Hypertension; Ketanserin; Receptors, Serotonin | 1987 |
134 trials available for ketanserin and Hypertension
| Article | Year |
|---|---|
Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Dihydralazine; Double-Blind Method; Female; Gestational Age; Hospita | 2015 |
Population pharmacokinetics of ketanserin in pre-eclamptic patients and its association with antihypertensive response.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Infusions, Intravenous; Ketanserin; Me | 2005 |
Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Ketanserin; Piperidines; Serotonin Antagonists | 1983 |
The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials a | 1984 |
Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combinatio | 1984 |
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1983 |
Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.
Topics: Adult; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Female; Hemodynamics; | 1984 |
[Serotonin antagonists in the treatment of hypertension].
Topics: Administration, Oral; Clinical Trials as Topic; Female; Humans; Hypertension; Infusions, Parenteral; | 1984 |
Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Hypertension; Ketanserin; Ma | 1984 |
Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Femal | 1984 |
Ketanserin in essential hypertension: effects during rest and exercise.
Topics: Antihypertensive Agents; Blood Pressure; Catecholamines; Heart Rate; Humans; Hypertension; Ketanseri | 1983 |
Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
Topics: Adrenal Glands; Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Ketanserin; M | 1984 |
The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Depression, Ch | 1981 |
The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1981 |
[Cross-over study on the effects of ketanserin vs enalapril in the treatment of hypertension].
Topics: Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Evaluation; Enalapril; Female; Huma | 1995 |
The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Anesthesia, General; Antihypertensive Agents; Double-Blin | 1995 |
Use of ketanserin in the treatment of hypertension following coronary artery surgery.
Topics: Aged; Blood Pressure; Central Venous Pressure; Coronary Artery Bypass; Double-Blind Method; Female; | 1994 |
[Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension].
Topics: Administration, Oral; Adult; Aldosterone; Cholesterol; Epinephrine; Female; Humans; Hypertension; Ke | 1993 |
Effect of intravenous ketanserin on arterial and intracranial pressures in patients with systemic hypertension following intracerebral haemorrhage.
Topics: Blood Pressure; Cerebral Hemorrhage; Female; Humans; Hypertension; Injections, Intravenous; Intracra | 1993 |
Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic-hyperinsulinemic clamp technique.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; | 1995 |
A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery.
Topics: Aged; Antihypertensive Agents; Coronary Vessels; Double-Blind Method; Hemodynamics; Humans; Hyperten | 1997 |
Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia.
Topics: Adult; Antihypertensive Agents; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 1997 |
Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dihydralazine; Double-Blind Method; Female; Fetal De | 1997 |
The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dihydralazine; Female; Heart Rate; H | 1998 |
The optimal dosage of ketanserin for patients with severe hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Double-Blind Method; Female; Humans; Hypertension; | 2002 |
[A cross-over study of ketanserin compared to placebo, beta-adrenergic blockader, diuretic and alpha 1-adrenergic blockader. Cooperative research in the USSR (the Cooperative Program to Study New Preparations in the Prevention of Arterial Hypertension). W
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Diuretics; Drug Th | 1991 |
Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetic Angiopathies; Foot Ulcer; Humans; Hypertensi | 1991 |
[Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin].
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Female; Humans; Hypertension; Ketanserin; Leg; | 1991 |
The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or alpha 1-adrenergic receptors.
Topics: Adult; Aged; Drug Interactions; Female; Forearm; Hemodynamics; Humans; Hypertension; Infusions, Intr | 1991 |
Effect of the acute sublingual administration of ketanserin in hypertensive patients.
Topics: Administration, Oral; Administration, Sublingual; Aged; Blood Pressure Monitors; Female; Humans; Hyp | 1991 |
Ketanserin and hydrochlorothiazide in the treatment of arterial hypertension.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hyperten | 1991 |
Ketanserin in the treatment of hypertension: a multicentre dose-finding study in China.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; | 1991 |
Serotonin antagonism reduces the adverse symptoms of beta blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bendroflumethiazide; Female; Humans; Hy | 1990 |
Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group.
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Double-Blind Method; Electrocardiography; Female; Hemo | 1990 |
[Short and medium term evaluation of captopril-ketanserin combination in mild to moderate arterial hypertension].
Topics: Adult; Aged; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension | 1990 |
Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension.
Topics: Atrial Natriuretic Factor; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Humans; Hypert | 1990 |
Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertension.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hype | 1990 |
A screening programme for hypertension in general practice.
Topics: Adult; Aged; Aged, 80 and over; Family Practice; Female; Humans; Hypertension; Ketanserin; Male; Mas | 1990 |
[The effect of acute administration of ketanserin on the peripheral metabolism of serotonin and hemodynamic indicators in hypertensive patients].
Topics: Adult; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Serotonin | 1990 |
The antihypertensive efficacy of ketanserin in the elderly evaluated by ambulatory blood pressure measurement.
Topics: Aged; Ambulatory Care; Blood Pressure; Blood Pressure Determination; Dose-Response Relationship, Dru | 1990 |
Oral dosing with ketanserin to control high blood pressure in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged | 1990 |
Ketanserin and captopril interaction in the treatment of essential hypertensives.
Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combi | 1990 |
A placebo-controlled crossover study of ketanserin in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Electrolytes; Female; Heart Rate; Huma | 1990 |
Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension.
Topics: Aged; Blood Pressure; Double-Blind Method; Enalapril; Female; Heart Rate; Humans; Hypertension; Keta | 1990 |
Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting.
Topics: Antihypertensive Agents; Coronary Artery Bypass; Heart Rate; Hemodynamics; Humans; Hypertension; Ket | 1990 |
Hemodynamic response to chronic ketanserin treatment in essential hypertension.
Topics: Adult; Cardiac Output; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Hemodynami | 1985 |
Double-blind comparison of ketanserin with propranolol in hypertensive patients: interim report.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
Clinical studies with ketanserin in hypertension.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Erythrocyte Deformability; Female; Humans | 1985 |
Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Humans; Hypertensi | 1985 |
Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Hea | 1985 |
Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clin | 1985 |
Effect of ketanserin in primary aldosteronism.
Topics: Aldosterone; Blood Pressure; Humans; Hydrocortisone; Hyperaldosteronism; Hypertension; Ketanserin; P | 1985 |
Ketanserin and red blood cell sodium content in hypertension.
Topics: Adult; Aged; Erythrocyte Deformability; Erythrocytes; Humans; Hypertension; Ketanserin; Middle Aged; | 1985 |
Effects of intravenous ketanserin on severely hypertensive patients with double-blind crossover assessment of central side-effects.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; In | 1987 |
Ketanserin versus propranolol in the treatment of mild and moderate essential hypertension: corroboration with ambulatory blood pressure monitoring.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; | 1987 |
Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter study.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Flushing; Heart Rate; Humans; Hyperte | 1987 |
Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial.
Topics: Blood Pressure; Body Weight; Central Nervous System; Clinical Trials as Topic; Female; Heart Rate; H | 1987 |
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Antihypertensive Agents; Blood Pressure; Clin | 1987 |
Antihypertensive efficacy of the combination of ketanserin + thiazide in hypertensives older than 50 years.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Dizziness; Drug Therapy, Combination; Female; Humans | 1987 |
Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily.
Topics: Blood Pressure; Drug Therapy, Combination; Erectile Dysfunction; Fatigue; Heart Rate; Humans; Hydroc | 1987 |
Multicenter study with ketanserin in essential hypertension: an Argentine experiment.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Central Nervous System; Clinical Trials as Topic; Fe | 1987 |
Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Humans | 1987 |
Renal hemodynamic effects of ketanserin therapy in essential hypertension.
Topics: Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Middle Aged; Renal | 1987 |
Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Topics: Adult; Affect; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Mid | 1987 |
Serum cholesterol during ketanserin and propranolol administration in hypertensive patients.
Topics: Body Weight; Cholesterol; Female; Heart Rate; Humans; Hypertension; Ketanserin; Lipoproteins, HDL; L | 1987 |
Experience with ketanserin and ritanserin in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1988 |
Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Hemodynamics; Horm | 1988 |
Double-blind comparison of ketanserin and propranolol in hypertensive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Blood Pressure; Body Weight; Chromatography, High | 1988 |
Haemodynamic effects of ketanserin in the treatment of hypertension following CABG: a double-blind, placebo-controlled study.
Topics: Blood Pressure; Cardiac Output; Central Venous Pressure; Coronary Artery Bypass; Double-Blind Method | 1989 |
Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.
Topics: Arm; Blood Pressure; Brachial Artery; Double-Blind Method; Hand; Humans; Hypertension; Ketanserin; M | 1989 |
Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fema | 1989 |
Ketanserin in the treatment of essential hypertension. A double blind trial against metoprolol followed by one-year open treatment.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Femal | 1989 |
Clinical investigation of the effect of ketanserin: a new antihypertensive drug.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Female; Heart Rate; Huma | 1989 |
[Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation].
Topics: Blood Pressure; Cardiac Output; Coronary Artery Bypass; Coronary Disease; Ferricyanides; Heart Rate; | 1989 |
An evaluation of ketanserin therapy for the hypertensive diabetic patient.
Topics: Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Bl | 1989 |
A double-blind comparative study of ketanserin with atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension | 1989 |
Orally dissolved ketanserin in acute treatment of hypertensive patients: a controlled study.
Topics: Administration, Oral; Aged; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Middle Aged; | 1989 |
Long-term antihypertensive efficacy of ketanserin plus chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Drug Administrat | 1989 |
[Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Atenolol; Blood Pressure; Drug Therapy, Combination; Fema | 1989 |
Effect of ketanserin on sodium nitroprusside requirements, arterial pressure control and heart rate following coronary artery bypass surgery.
Topics: Adult; Aged; Blood Pressure; Coronary Artery Bypass; Double-Blind Method; Female; Ferricyanides; Hea | 1989 |
Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atenolol; Diuretics; Drug Therapy, Combination; Female; | 1989 |
Ketanserin--a new antihypertensive agent.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Diuretics; Dose-Response Relationship, Drug; | 1986 |
Ketanserin: haemodynamic effects and mechanism of action.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Humans; Hype | 1986 |
Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Hea | 1986 |
Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Histamine H2 Antagonists; Humans; Hyper | 1987 |
Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzothiadiazines; Blood Pressure; Body Weight; Clinical T | 1987 |
Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blin | 1987 |
Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Diuretics; Drug Synergism; Drug Therapy, C | 1988 |
Serotonergic blockade compared with beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin with propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Bleeding Time; Blood Platelets; Blood Pressure; Double-Blind Met | 1988 |
A comparative study of ketanserin and metoprolol in essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1985 |
Ketanserin hypertension and chronic alcoholism DB study in 40 patients.
Topics: Alcoholism; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; Ketanserin; Male; Piperid | 1985 |
Chronic effect of ketanserin in mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Double-Blind Method; Female | 1986 |
Effects of ketanserin on ambulatory blood pressure monitoring in patients with essential hypertension.
Topics: Adult; Ambulatory Care; Blood Pressure Determination; Female; Humans; Hypertension; Ketanserin; Male | 1986 |
Comparison of ketanserin and pindolol in hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Ketanserin; Male | 1986 |
A comparative study of ketanserin and metoprolol in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Huma | 1986 |
Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1986 |
Ketanserin versus metoprolol in the treatment of essential hypertension.
Topics: Adult; Aged; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Ketanserin; Male; Metoprol | 1986 |
Clinical experience with ketanserin in the treatment of hypertension.
Topics: Double-Blind Method; Heart Rate; Humans; Hypertension; Ketanserin; Metoprolol; Piperidines | 1986 |
Ketanserin in the treatment of mild hypertension in elderly patients: preliminary results of a controlled double-blind trial.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Ketanserin; Male; | 1986 |
Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
Topics: Aged; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged; Piperidines | 1986 |
[Multicenter study with 3 different doses of ketanserin in essential arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Administration | 1985 |
Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects.
Topics: Adult; Aldosterone; Blood Pressure; Cholesterol; Drug Evaluation; Female; Heart Rate; Humans; Hypert | 1986 |
Influence of ketanserin pretreatment on the haemodynamic responses to sternotomy.
Topics: Drug Evaluation; Hemodynamics; Humans; Hypertension; Indoles; Intraoperative Complications; Ketanser | 1986 |
Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Coagulation; Blood Pressure; Doub | 1986 |
Ketanserin in essential hypertension. Effects of blood pressure on renal hemodynamics.
Topics: Animals; Blood Pressure; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Ketanserin; | 1988 |
Prolongation of the QT interval by ketanserin.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Huma | 1988 |
Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
Topics: Adult; Aged; Alcoholism; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1988 |
Comparative trial of ketanserin or bendrofluazide as add-on therapy in hypertensive patients uncontrolled on a beta-blocker alone.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Bendroflumethiazide; Clinical Trials as Topic; Double-B | 1988 |
Ketanserin, an effective third-line agent in primary hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1988 |
Comparison of ketanserin with captopril in older hypertensives. A double-blind randomised trial.
Topics: Aged; Aged, 80 and over; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Administrati | 1988 |
Comparative double-blind study of ketanserin versus propranolol in the treatment of essential hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Hu | 1988 |
Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypertension; Ketanserin; Lipids; Male; Middl | 1988 |
Ketanserin in the treatment of diabetes-associated hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Hemodynamics; Humans; | 1988 |
Antihypertensive response to ketanserin: influence of race and weight.
Topics: Adult; Aged; Aldosterone; Black People; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hyp | 1988 |
Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Complications; Double-Blind Method; Female; Hum | 1988 |
Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
Topics: Adult; Blood Pressure; Body Weight; Exercise Test; Heart Rate; Hemodynamics; Humans; Hypertension; K | 1985 |
Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Adminis | 1985 |
Controlled trial of ketanserin in hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Huma | 1985 |
Correcting for the bias caused by drop-outs in hypertension trials.
Topics: Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blind Method; Humans; Hypertensio | 1988 |
Comparative study of ketanserin and hydrochlorothiazide in essential hypertension. Janssen Research Group.
Topics: Blood Pressure; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Ketanserin; Random Allocation | 1988 |
[Clinical profile of a new antihypertensive agents. Ketanserin].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Hemodynamics | 1988 |
Effects of chronic antihypertensive treatment with ketanserin versus metoprolol on blood pressure and large arteries' compliance in humans: a cross-over double-blind study.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Brachial Artery; Cardiac Output; Compliance; Double- | 1988 |
Ketanserin compared to nifedipine and methyldopa in patients aged above 50 years: two international multicentre studies. For the International Study Group.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate | 1986 |
Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; | 1987 |
Ketanserin and the cardiovascular response to intubation: a preliminary report.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Intubation, Intr | 1987 |
Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
Topics: Adult; Blood Pressure; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Mid | 1988 |
Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension.
Topics: Adult; Aged; Aging; Angiotensin II; Blood Pressure; Calcium; Humans; Hypertension; Intracellular Mem | 1988 |
Blood pressure during a combination of ketanserin and hydrochlorothiazide.
Topics: Aged; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Ketanser | 1987 |
Double-blind comparison of ketanserin with placebo in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Clinical Trials as Topic; Double-Blind M | 1986 |
Ketanserin in the treatment of essential hypertension. A double-blind study against metoprolol and a further long-term open treatment.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Huma | 1986 |
Comparison of ketanserin and metoprolol in the treatment of essential hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male | 1987 |
Combined pharmaco-EEG and pharmacopsychological study to estimate CNS effects of ketanserin in hypertensive patients.
Topics: Adult; Aged; Automobile Driving; Blood Pressure; Central Nervous System; Electroencephalography; Fem | 1986 |
The influence of ketanserin, droperidol and hydergine on postoperative hypertension during early recovery following major abdominal surgery.
Topics: Abdomen; Adult; Aged; Antihypertensive Agents; Dihydroergotoxine; Double-Blind Method; Droperidol; F | 1987 |
[Prolonged treatment with ketanserin in essential hypertension and comparison with metoprolol].
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hypertension; Ketanserin; Mal | 1985 |
142 other studies available for ketanserin and Hypertension
| Article | Year |
|---|---|
Death-Associated Protein Kinase 3 Inhibitors Identified by Virtual Screening for Drug Discovery in Cancer and Hypertension.
Topics: Death-Associated Protein Kinases; Drug Discovery; Early Detection of Cancer; Humans; Hypertension; K | 2022 |
5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Disease Models, Animal; Endothelium, Vascular; Hu | 2002 |
Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Topics: Adult; Animals; Binding Sites; Blood Platelets; Blood Pressure; Cats; Dose-Response Relationship, Dr | 2002 |
Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Female; Hypertension; Hypertrophy, Left Ventricular; Ketanserin; Kidney Fai | 2003 |
Ketanserin stabilizes blood pressure in conscious spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Consciousness; Hypertension; Ketanserin; Male; Rats; Rats, Inbred SHR | 2003 |
Comparative study of sinoaortic denervated rats and spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Cardiovascular System; Hemodynamics; H | 2003 |
Ketanserin in women with chronic hypertension and underlying thrombophilia.
Topics: Adult; Antihypertensive Agents; Female; Fetal Growth Retardation; HELLP Syndrome; Humans; Hypertensi | 2004 |
Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke.
Topics: Anesthesia; Animals; Brain; Brain Ischemia; Corpus Striatum; Disease Models, Animal; Glutamic Acid; | 2005 |
Arterial baroreflex: a novel target for preventing stroke in rat hypertension.
Topics: Animals; Baroreflex; Blood Pressure; Drug Delivery Systems; Female; Hypertension; Ketanserin; Male; | 2007 |
Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
Topics: Animals; Antibodies, Monoclonal; Antihypertensive Agents; Baroreflex; Blood Pressure; Brain; Disease | 2007 |
Acute effects of antagonist of S2-receptors.
Topics: Adult; Blood Pressure; Drug Evaluation; Female; Humans; Hydroxyindoleacetic Acid; Hypertension; Keta | 1984 |
Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
Topics: Adrenergic alpha-Agonists; Animals; Arteries; Blood Pressure; Calcium; Dogs; Guinea Pigs; Hypertensi | 1981 |
Ketanserin: a selective serotonin antagonist.
Topics: Cardiovascular System; Humans; Hypertension; Ketanserin; Piperidines; Receptors, Serotonin; Serotoni | 1982 |
Ketanserin treatment in essential hypertension.
Topics: Antihypertensive Agents; Humans; Hypertension; Ketanserin; Piperidines | 1984 |
Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Piperidines; | 1984 |
Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
Topics: Amidines; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; In Vitro Techniques; Ketan | 1984 |
Excitatory and inhibitory effects of 5-hydroxytryptamine in mesenteric arteries of spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cyproheptadine; Drug Synergism; Hypertension; In Vitro Techniques; Ketanser | 1984 |
The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery.
Topics: Coronary Artery Bypass; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Infusions, Parentera | 1983 |
Ketanserin in the treatment of hypertension following coronary artery bypass surgery. A preliminary study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Bypass; Humans; Hypertension; | 1983 |
Prophylactic use of ketanserin in a patient with carcinoid syndrome.
Topics: Female; Humans; Hypertension; Intraoperative Complications; Ketanserin; Malignant Carcinoid Syndrome | 1983 |
Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Ketanserin; Kinetics; Male; M | 1983 |
Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Heart Rate; Hemodynamics; Hypertension; K | 1983 |
Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise.
Topics: Adult; Blood Pressure; Body Fluids; Body Weight; Cardiac Output; Female; Heart Rate; Hemodynamics; H | 1983 |
Intrapartum treatment of preeclamptic hypertension by ketanserin--a serotonin receptor antagonist.
Topics: Adult; Antihypertensive Agents; Delivery, Obstetric; Female; Humans; Hydralazine; Hypertension; Infa | 1984 |
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
Topics: Adult; Aged; Cardiac Output; Female; Heart Rate; Humans; Hypertension; Ketanserin; Kidney; Male; Mid | 1982 |
Determination of ketanserin in human plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Hypertension; Ketanserin; Piperidines; Time Factors | 1983 |
Is prevention of hypertension after open heart surgery possible by blocking 5HT2-receptors with ketanserin?
Topics: Adult; Aged; Anesthesia; Aortic Valve; Coronary Artery Bypass; Heart Valve Prosthesis; Hemodynamics; | 1982 |
Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs.
Topics: Aging; Animals; Blood Cell Count; Blood Pressure; Blood Viscosity; Dogs; Erythrocyte Membrane; Hyper | 1982 |
5-Hydroxytryptamine2B receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats.
Topics: Algorithms; Animals; Antihypertensive Agents; Blood Pressure; Data Interpretation, Statistical; Deso | 1995 |
The effect of ketanserin upon postoperative blood pressure, cerebral blood flow and oxygen metabolism in patients subjected to craniotomy for cerebral tumours.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Temperature; Brain; Brain Neoplasms; Cere | 1995 |
Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats.
Topics: Anemia; Animals; Blood Platelets; Endothelium, Vascular; Erythropoietin; Hypertension; Ketanserin; K | 1995 |
Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Heart Rate; Hypertension; Infusions, Intraven | 1993 |
[Effectiveness of ketanserin in the treatment of light-to-moderate arterial hypertension].
Topics: Adult; Blood Pressure; Cholesterol, HDL; Drug Evaluation; Female; Humans; Hypertension; Ketanserin; | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Epin | 1993 |
Cardiovascular activity of A-74283, a 5-hydroxytryptamine 1A agent, in the spontaneously hypertensive rat.
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cisterna Magna; Decerebrat | 1998 |
Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat.
Topics: Animals; Benzamides; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, Drug; Hyperte | 2001 |
Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension.
Topics: Animals; Carbazoles; Desoxycorticosterone; Dose-Response Relationship, Drug; Fluorobenzenes; Hyperte | 2002 |
[Cardiac interactions between ketanserin and the calcium antagonist nifedipine].
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiac Complexes, Premature; Drug Interactions; Drug Th | 1992 |
[Role of serotonin and its receptors in the pathogenesis of arterial hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Brain; Humans; Hypertension; Ketanserin; Recepto | 1992 |
[Effect of ketanserin on arterial baroreflex-blood pressure control in conscious hypertensive rats].
Topics: Animals; Blood Pressure; Hypertension; Hypertension, Renovascular; Ketanserin; Male; Pressoreceptors | 1992 |
Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Cardiomegaly; Celiprolol; Echocardiography; Femal | 1992 |
Effects of ketanserin on blood pressure variability in conscious spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Ketanserin; Male; Microcomputers; Ra | 1992 |
Effect of N(G)-nitro-L-arginine methyl ester on the hypotensive and hypertensive responses to 5-hydroxytryptamine in pithed rats.
Topics: Animals; Appetite Depressants; Arginine; Blood Pressure; Drug Interactions; Endothelium, Vascular; H | 1992 |
Ketanserin for hypertension after upper gastrointestinal surgery.
Topics: Adrenergic alpha-Antagonists; Digestive System Surgical Procedures; Humans; Hypertension; Ketanserin | 1991 |
Ketanserin for hypertension after upper gastrointestinal surgery.
Topics: Adult; Humans; Hypertension; Ketanserin; Male; Postoperative Complications; Stomach Neoplasms | 1991 |
Platelet serotonin-LDL interaction in essential hypertension.
Topics: Adult; Age Factors; Aged; Blood Platelets; Female; Humans; Hypertension; Ketanserin; Lipoproteins, L | 1991 |
Haemodynamic effects of ketanserin following coronary artery bypass grafting.
Topics: Adult; Aged; Blood Pressure; Coronary Artery Bypass; Heart Rate; Hemodynamics; Humans; Hypertension; | 1991 |
[Effect of ketanserin on central hemodynamics and myocardial contractility].
Topics: Adult; Aged; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Middle Aged; Myocardial Contracti | 1991 |
Cardiac effects of serotonin in hypertension.
Topics: Animals; Coronary Circulation; Dose-Response Relationship, Drug; Heart; Heart Rate; Hypertension; In | 1991 |
Haemodynamic and metabolic effects of ketanserin in dyslipidaemic hypertensive subjects.
Topics: Adult; Aged; Diet, Reducing; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Lipids; Male; M | 1991 |
[Effects of ketanserin on glucose metabolism in hypertensive diabetic subjects].
Topics: Diabetes Mellitus, Type 2; Electrolytes; Female; Glucose; Hemodynamics; Humans; Hypertension; Insuli | 1990 |
Antihypertensive treatment with ketanserin shows no evidence of vascular serotonin2-receptor and alpha 1-adrenoceptor blockade.
Topics: Adrenergic alpha-Antagonists; Adult; Arteries; Blood Pressure; Female; Humans; Hypertension; Ketanse | 1990 |
Absence of effects of ketanserin on renal prostacyclin and thromboxane A2 in essential hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Epoprostenol; Female; Humans; Hypertension; Ketanserin; K | 1991 |
[Prolongation of the QT interval and torsade de pointes caused by ketanserin].
Topics: Aged; Aged, 80 and over; Aortic Valve Insufficiency; Electrocardiography; Humans; Hypertension; Keta | 1990 |
The use of ketanserin for postoperative hypertension after abdominal surgery.
Topics: Abdomen; Adult; Aged; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged; Postoperative Com | 1990 |
Effects of ketanserin on left ventricular hypertrophy in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Cardiomegaly; Cholesterol; Electrocardiography; Female; Heart Rate; Hum | 1990 |
Regression of left ventricular hypertrophy and systolic function in hypertensive patients during long-term treatment with ketanserin.
Topics: Adult; Angiocardiography; Blood Pressure; Cardiomegaly; Echocardiography; Female; Heart Rate; Humans | 1990 |
Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives.
Topics: Aged; Blood Pressure; Cardiac Output; Cardiomegaly; Echocardiography; Female; Heart Rate; Humans; Hy | 1990 |
Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension.
Topics: Adult; Aged; Aging; Blood Platelets; Humans; Hypertension; Ketanserin; Kinetics; Middle Aged; Recept | 1990 |
Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
Topics: Adult; Apolipoproteins; Blood Pressure; Cholesterol; Female; Humans; Hypertension; Ketanserin; Lipop | 1990 |
Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.
Topics: Arterioles; Blood Pressure; Blood Viscosity; Female; Hemodynamics; Humans; Hypertension; Ketanserin; | 1990 |
Effect of ketanserin on pain perception in arterial hypertension.
Topics: Adult; Blood Pressure; Dental Pulp; Electric Stimulation; Female; Humans; Hypertension; Ketanserin; | 1990 |
Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?
Topics: Adult; Aged; Aged, 80 and over; Aging; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged | 1990 |
Antihypertensive therapy with ketanserin: effects on central and renal hemodynamics, and microalbuminuria.
Topics: Adult; Albuminuria; Cardiac Output; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypert | 1990 |
[Ketanserin. A new antihypertensive agent with an antagonistic effect on serotonin].
Topics: Animals; Humans; Hypertension; Ketanserin; Receptors, Serotonin | 1990 |
Ketanserin in chronic treatment of hypertension in type 2 diabetes mellitus.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose; Glucose Tol | 1990 |
Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Male; Piperi | 1985 |
Platelet serotonin in essential hypertension and in mental depression.
Topics: Adult; Antidepressive Agents; Blood Platelets; Depressive Disorder; Female; Humans; Hypertension; Ke | 1985 |
Serotonergic mechanisms and blood pressure in sheep.
Topics: Adrenergic alpha-Antagonists; Adrenocorticotropic Hormone; Animals; Blood Pressure; Female; Heart Ra | 1985 |
The acute antihypertensive effect of ketanserin increases with age.
Topics: Adult; Aged; Aging; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Injection | 1985 |
Ketanserin: a possible tool for studying the role of serotonin in hypertension.
Topics: Aldosterone; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Middle Ag | 1985 |
A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Diuretics; Female; Humans; Hypertension; Ketanse | 1985 |
Ketanserin in the acute management of severe hypertension.
Topics: Adolescent; Adult; Blood Pressure; Creatinine; Female; Heart Rate; Humans; Hypertension; Ketanserin; | 1985 |
Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hydroxyindoleacetic Acid; Hypertension; Ketanseri | 1985 |
Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease.
Topics: Adult; Aged; Blood Platelets; Erythrocyte Deformability; Erythrocytes; Female; Humans; Hypertension; | 1985 |
Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension.
Topics: 5,6-Dihydroxytryptamine; Animals; Desoxycorticosterone; Dose-Response Relationship, Drug; Hydroxyind | 1987 |
Effects of ketanserin on hemodynamics and baroreflex effects in conscious spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Atropine; Hemodynamics; Hypertension; Ketanserin; Nitroprusside; Pressorece | 1987 |
The role of serotonin in cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hypertension; Ketanserin; Serotonin | 1987 |
Ketanserin in parenteral treatment of acute essential hypertension: a dose-response curve.
Topics: Adult; Aged; Blood Pressure; Dizziness; Dose-Response Relationship, Drug; Drug Evaluation; Female; H | 1987 |
Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Male; Phenyl | 1988 |
Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension.
Topics: Aldosterone; Blood Pressure; Extremities; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male | 1988 |
Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.
Topics: Adult; Age Factors; Aged; Female; Humans; Hydroxyindoleacetic Acid; Hypertension; Ketanserin; Male; | 1988 |
Ketanserin in the treatment of systemic hypertension during and following coronary artery bypass surgery.
Topics: Blood Pressure; Cardiac Output; Coronary Artery Bypass; Fentanyl; Heart Rate; Humans; Hypertension; | 1989 |
[Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Exercise; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; M | 1989 |
[Clinico-therapeutic experience with a new antihypertensive drug, ketanserin, in elderly patients].
Topics: Aged; Aged, 80 and over; Drug Evaluation; Female; Humans; Hypertension; Ketanserin; Male; Middle Age | 1989 |
An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Anesthesia; Animals; Blood Pressure; Ergolines; Heart Rate; | 1989 |
[Clinical application of serotonin antagonists in the treatment of hypertension].
Topics: Hemodynamics; Humans; Hypertension; Ketanserin; Receptors, Serotonin; Serotonin; Serotonin Antagonis | 1989 |
[Clinical and hemodynamic effects of medium-term ketanserin treatment in 2 compared groups of obese and non-obese hypertensive patients].
Topics: Adult; Blood Pressure; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male | 1989 |
Can atherosclerotic complications be prevented?
Topics: Arteriosclerosis; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Ketanserin | 1989 |
Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
Topics: Adult; Aged; Blood Platelets; Blood Pressure; Female; Humans; Hypertension; Ketanserin; Male; Middle | 1989 |
Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension.
Topics: Animals; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Electric Stimulation; Hyperten | 1989 |
[The effects of ketanserin on vascular eicosanoid system in spontaneously hypertensive rats and their implications].
Topics: Animals; Blood Pressure; Cell Division; Cells, Cultured; Hypertension; Ketanserin; Muscle, Smooth, V | 1989 |
[Observations with ketanserin].
Topics: Arteriosclerosis; Humans; Hypertension; Ketanserin | 1989 |
Carcinoid syndrome: the combined use of ketanserin and octreotide in the management of an acute crisis during anaesthesia.
Topics: Anesthesia; Breast Neoplasms; Carcinoid Tumor; Female; Humans; Hypertension; Intraoperative Complica | 1989 |
[Ketanserin. Lowering blood pressure using serotonin antagonists].
Topics: Blood Pressure; Humans; Hypertension; Ketanserin; Muscle, Smooth, Vascular | 1989 |
Mechanism of action of ketanserin in hypertension and vasospastic disease.
Topics: Blood Pressure; Drug Therapy, Combination; Fingers; Humans; Hypertension; Ketanserin; Muscle, Smooth | 1987 |
Kinetic-dynamic relationships and antihypertensive mechanisms of ketanserin in essential hypertension.
Topics: Dose-Response Relationship, Drug; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged; Pheny | 1988 |
Treatment of arterial hypertension with ketanserin in mono- and combination therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Drug Therapy, Combination; Female; Follow- | 1985 |
[Ketanserin in association with a beta blocker and a diuretic in the treatment of essential hypertension].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hypertens | 1985 |
[Marginal notes on ketanserin].
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged; Substance-Rela | 1989 |
Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Decerebrate State; Dose-Response Relationship, Drug; Electric Stimulation; | 1985 |
Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
Topics: Adult; Alcoholism; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Ketanserin | 1986 |
Symposium on serotonin and cardiovascular regulation: a new approach to hypertension. Satellite symposium of the Second European Meeting on Hypertension. 9 June 1985, Milan, Italy.
Topics: Animals; Humans; Hypertension; Ketanserin; Piperidines; Serotonin; Serotonin Antagonists | 1986 |
Nitroprusside and ketanserin in the treatment of postoperative hypertension following coronary artery bypass grafting: a haemodynamic and ventilatory comparison.
Topics: Blood Pressure; Coronary Artery Bypass; Female; Ferricyanides; Heart Rate; Humans; Hypertension; Ket | 1986 |
Serotonin and the blood vessel wall.
Topics: Animals; Blood Platelets; Heart; Hypertension; Ketanserin; Muscle, Smooth, Vascular; Piperidines; Ra | 1986 |
Serotonin and cardiovascular regulation: a new approach to hypertension.
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ketanserin; Piperidines; S | 1986 |
Renal effects of ketanserin in essential hypertension.
Topics: Adult; Angiotensins; Female; Glomerular Filtration Rate; Humans; Hypertension; Ketanserin; Kidney; M | 1986 |
Regional haemodynamics and antihypertensive effects during long-term ketanserin treatment.
Topics: Female; Hemodynamics; Humans; Hypertension; Ketanserin; Long-Term Care; Male; Middle Aged; Piperidin | 1986 |
Peri-operative management of carcinoid syndrome using ketanserin.
Topics: Aged; Antihypertensive Agents; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Hypertensi | 1986 |
Intrapartum treatment of preeclamptic hypertension by ketanserin.
Topics: Blood Pressure; Female; Fetal Heart; Heart Rate; Humans; Hypertension; Ketanserin; Obstetric Labor C | 1986 |
Atrial natriuretic peptide in human essential hypertension.
Topics: Adult; Aged; Atrial Natriuretic Factor; Blood Pressure; Dihydropyridines; Female; Heart Rate; Humans | 1987 |
Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Hypertension; Ketan | 1985 |
[Hypotensive effect of ketanserin and evaluation of its alpha-blocking activity].
Topics: Adult; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Metoprolol; | 1986 |
[Symposium. Ketanserin: Serotonin antagonism is a new therapeutic principle in the older hypertensive patient. 24 September 1988, Frankfurt. Abstracts].
Topics: Aged; Humans; Hypertension; Ketanserin | 1988 |
Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
Topics: Animals; Blood Pressure; Cardiac Output; Heart Rate; Hypertension; Ketanserin; Phenylephrine; Piperi | 1987 |
Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Male; Piperidines; Prazosin; Pressore | 1988 |
[Serotonin antagonists for the treatment of hypertension].
Topics: Antihypertensive Agents; Humans; Hypertension; Ketanserin; Vascular Resistance | 1988 |
Ketanserin concentration-effect relationships in individual hypertensive patients.
Topics: Aging; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Middle Aged | 1988 |
Haemodynamic changes associated with long term antihypertensive therapy with ketanserin.
Topics: Adult; Blood Pressure; Drug Administration Schedule; Female; Hemodynamics; Humans; Hypertension; Ket | 1988 |
Antihypertensive effect of long term ketanserin in elderly essential hypertensive patients. Assessment of left ventricular function at rest and during exercise.
Topics: Aged; Exercise; Female; Heart; Heart Ventricles; Hemodynamics; Humans; Hypertension; Ketanserin; Mal | 1988 |
Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.
Topics: Drug Administration Schedule; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male; Serotoni | 1988 |
Effect of ketanserin on lipoproteins in patients with essential hypertension.
Topics: Adult; Aged; Female; Humans; Hypertension; Ketanserin; Lipoproteins; Male; Middle Aged | 1988 |
Influence of ketanserin on glucose and lipid metabolism in diabetic patients with hypertension.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Ketanserin; Lipids; M | 1988 |
Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
Topics: Humans; Hypertension; Intermittent Claudication; Ketanserin; Raynaud Disease | 1988 |
The relevance of serotonin antagonism in the treatment of hypertension.
Topics: Hemodynamics; Humans; Hypertension; Ketanserin; Serotonin; Serotonin Antagonists | 1988 |
Effects of long term oral administration of ketanserin and trichlormethiazide on blood pressure in stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Cerebrovascular Disorders; Hypertension; Ketanserin; | 1988 |
[Specific aspects of the action of serotonin and ketanserin in the regulation of arterial pressure].
Topics: Blood Pressure; Hemodynamics; Humans; Hypertension; Ketanserin; Serotonin | 1988 |
[What does the introduction of ketanserin for the treatment of arterial hypertension represent?].
Topics: Aged; Antihypertensive Agents; Drug Administration Schedule; Hemodynamics; Humans; Hypertension; Ket | 1988 |
[Effects of chronic oral administration of ketanserin and trichlormethiazide on blood pressure in stroke-prone spontaneously hypertensive rats].
Topics: Administration, Oral; Animals; Blood Pressure; Diuresis; Drug Synergism; Drug Therapy, Combination; | 1988 |
Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension.
Topics: Adult; Blood Pressure; Diabetic Angiopathies; Female; Humans; Hypertension; Ketanserin; Male; Middle | 1988 |
Ketanserin decreases sympathetic nervous activity in hypertension.
Topics: Animals; Blood Pressure; Hypertension; Ketanserin; Male; Norepinephrine; Rats; Rats, Inbred SHR; Rat | 1988 |
[Clinical evaluation of KJK-945 (ketanserin) on a multicenter basis].
Topics: Anesthesia; Evaluation Studies as Topic; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged | 1987 |
The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects.
Topics: Aged; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Ketanserin; Male; M | 1987 |
Abstracts of the symposium on hypertension and the ageing cardiovascular system: the role of serotonin. Brussels, February 7, 1987.
Topics: Aging; Cardiovascular Physiological Phenomena; Humans; Hypertension; Ketanserin; Serotonin | 1987 |
The significance of ketanserin for the treatment of hypertension.
Topics: Administration, Oral; Drug Administration Schedule; Humans; Hypertension; Ketanserin | 1987 |
Pharmacokinetics of ketanserin in patients with essential hypertension.
Topics: Administration, Oral; Aged; Biological Availability; Female; Half-Life; Hemodynamics; Humans; Hypert | 1987 |
The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
Topics: Aged; Blood Pressure; Cardiopulmonary Bypass; Female; Humans; Hypertension; Ketanserin; Male; Middle | 1987 |
Profound hypotension after the first dose of ketanserin.
Topics: Aged; Female; Heart Rate; Humans; Hypertension; Hypotension; Ketanserin; Male; Middle Aged | 1987 |
Response to tilting in hypertensive patients receiving ketanserin.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Ketanserin; Male; Middle Aged; | 1986 |
Plasma concentrations of ketanserin in chronic hemodialysed patients.
Topics: Adult; Blood Pressure; Humans; Hypertension; Ketanserin; Kidney Failure, Chronic; Kinetics; Middle A | 1986 |
[Serotonin and cardiovascular regulation: new aspects of hypertension. Satellite symposium of the Second European Meeting on Hypertension. Milan, 9 June 1985].
Topics: Cardiovascular System; Humans; Hypertension; Ketanserin; Serotonin Antagonists | 1985 |